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Abstract
Virus filters are single-use devices that use a size-based separation process. In virus
filters, contaminating virus particles are retained while the therapeutic molecules pass through
the membrane pores. Virus filters are an essential component of the overall virus clearance
strategy. Sections 1 and 2 of this dissertation provide an introduction and extensive review of
monoclonal antibody (mAb) process development, where virus filtration is pivotal.
In section 3, prefiltration studies were performed with an industrially relevant IgG1 type
mAb using adsorptive and size-exclusion-based prefilters with different mechanisms of action.
This mAb has an isoelectric point range of 7.1 to 8.0 and a molecular weight (MW) of 148 kDa.
Decoupled prefiltration and virus filtration studies were conducted. We attempted to elute bound
species from the membrane to identify them. Permeate fractions from the prefilters were
introduced as feed fractions to a Planova BioEX (Asahi Kasei Medical, Tokyo, Japan)
commercial virus filter for flux decay studies. Prefiltration and virus filtration studies were
performed at different pH and ionic strength buffer conditions. By adjusting buffer conditions,
and choosing prefilters with an appropriate mechanism of action, increased selectivity for foulant
capture resulting in improved flux behavior during virus filtration could be achieved. Extensive
characterization was also performed for the various filtration fractions to determine molecular
species that increase fouling propensity in the virus filter and the efficacy of the different
prefilters at removing these species.
In section 4, prefiltration and flux decay studies on a Viresolve Pro (MilliporeSigma,
Billerica, MA) as well as the Planova BioEX virus filter was performed with another industrially
relevant mAb with an isoelectric point range of 5.95 - 6.55. The impact of excipients on mAb
fouling behavior was determined. The impact of buffer pH was also evaluated with one pH

condition below the isoelectric point (pI) of the mAb and another pH condition above the mAb
pI. Decoupled prefiltration was performed to evaluate the impact of different types of prefilters
on the filterability of this mAb. The pharmaceutical analysis system PA800 plus (SCIEX,
Redwood City, CA) was also used to characterize the various mAb fractions from prefiltration
and virus filtration. Dynamic light scattering (particle size analysis), size exclusion
chromatography, SDS PAGE, capillary electrophoresis, and MALDI mass spectrometry were
used for characterization.
In section 5, a new technique of fractionating close molecular weight biomolecules was
evaluated for virus clearance. The technique is known as internally staged ultrafiltration (ISUF),
where layers of ultrafiltration membranes operate in stages to fractionate biomolecules based on
differences in isoelectric points. The membranes of interest were the Pall Omega PES 300 kDa
molecular weight cutoff (MWCO) flat sheet membrane, Pall Omega PES 100 kDa MWCO
membrane, Millipore Ultracel 100kDa MWCO, and the Millipore Ultracel 30kDa MWCO. Virus
clearance studies were performed using internally staged ultrafiltration membranes in skin and
backing configurations.
Section 6 is an overall conclusion for this work showing major findings and identifying
areas for future study.
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1.0 General Introduction
1.1 Aim and Outline
This research aims to fill a significant knowledge gap: understanding virus prefiltration to
select an appropriate virus prefilter for a given biological drug substance. Today, virus prefilters
are tested in an arbitrary manner. Sterilizing grade filters such as 0.2-μm or 0.1-μm filters are
routinely used. When a significant flux decline of the virus filter is observed, prefilters with other
mechanisms of action such as ion exchange and hydrophobic interaction are investigated. This
research also explores virus clearance using a parvovirus known as Minute virus of mice (MVM)
and ultrafiltration membranes in the internally staged ultrafiltration (ISUF) mode.
The primary research methodology involved virus filtration of different monoclonal
antibodies (mAbs) in different buffer conditions and with multiple brands of virus filters and
prefilters. Virus filter parameters that play a role in filter fouling include filter chemistry,
membrane orientation, pore size distribution, and pore size gradient [1-5]. These experiments
yielded a large data set for predicting filterability and fouling propensity of mAbs under different
parameters. The impact of different formulation excipients on fouling behavior was explored.
Next, a molecular level characterization of the fouling species was performed to optimize
filtration conditions that enhance prefiltration performance. Finally, these results were used to
implement optimized prefiltration and virus filtration processes by leveraging the biophysical
properties of mAb feed streams.
1.2 Downstream Purification
Downstream purification of mammalian cell-derived therapeutic proteins involves
platform processes typically operated in a batch mode [6, 7]. The core role of downstream

1

purification is to purify the biological drug substance (biologic) and remove any pathogens that
could endanger the patient's life. Some unit operations involved in downstream purification are
affinity chromatography, chromatographic polishing steps, virus filtration, and
ultrafiltration/diafiltration (UF/DF). Downstream purification typically makes up 50-70 percent
of monoclonal antibody manufacturing costs. Virus filtration makes up about ten percent of
manufacturing costs [8].
Monoclonal antibody (mAb) downstream purification unit operations typically begin
with a capture step. The capture step consists of a resin-based affinity chromatography step such
as protein A. Protein A purification mechanism involves hydrophobic interactions between the
protein A ligand and the crystallizable fragment region of the antibody's heavy chain [9]. Other
factors, such as ionic interactions and hydrogen bonds, play a part in affinity chromatography
[10].
Two additional chromatography polishing steps are typically included, e.g., ion exchange
or hydrophobic interaction chromatography. One of these polishing steps could use a membrane
adsorber in place of a packed resin column. Chromatographic polishing steps purify the mAb and
eliminate non-desirables such as DNA, monomeric variants, host cell proteins, and oligomers of
the mAb [11].
Two unit operations (most commonly low pH hold and virus filtration) are targeted to
validate virus clearance [11]. Validation of adequate virus clearance is essential to obtain
approval for a manufacturing process [11, 12]. Other operations performed to exclude or
inactivate viruses, virus-like particles, and disease vectors include solvent/detergent treatment,
heat treatment, and UV/gamma irradiation [13-15].
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1.3 Optimization of Batch Processes in Downstream Purification
In the context of reducing manufacturing costs, each of the individual unit operations can
be optimized to minimize waste, mitigate fouling of single-use membranes, and reduce process
downtime. Virus filtration occurs downstream of protein A chromatography, usually after one or
more of the chromatographic polishing steps. Virus filtration typically involves highly purified
biologics. The virus filtration process is the final defense against adventitious virus
contamination of biologics. Virus filters are costly and can sometimes foul rapidly. The use of
prefilters to remove virus filter foulants before virus filtration extends the run-time and
productivity of the virus filter, thereby reducing manufacturing costs.
Batch processes have typically been the mainstay of the industrial-scale manufacture of
therapeutic proteins. There is a cascade of sequential unit operations in downstream processing
with a hold step between each operation. Process optimization of batch processes involves
evaluating unit operations in isolation and optimizing them. Nevertheless, batch processes ensure
the real-time availability of product quality parameters and critical quality attributes between unit
operations [16].
Interest in optimized bioprocessing that focuses on continuous processing is necessary
because of economic pressure to reduce the cost burden of paying patients who rely on lifesaving therapeutic proteins [16]. Economic competition is also a result of companies in emerging
economies using less overhead costs to produce biosimilars [16]. Continuous operations would
increase the manufacturer’s productivity and mass availability of these biologics.
Several approaches have been explored for optimized process development, including
experimental approaches, expert knowledge, and empirical modeling (in-silico methods) [17,
18]. Approaches adopted to explore continuous operations in downstream processing include
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multiple modular (disposable or regenerating) units programmed to switch from one bank to
another. At the same time, the cartridges are replaced or regenerated. Continuous
chromatographic separations have also been and are still being developed based on multi-column
systems [16]. Adaptations of continuous anion exchange chromatography for optimized
processes include periodic countercurrent chromatography [19], simulated moving bed
chromatography (SMB) [20], and multi-column countercurrent solvent gradient purification
(MCGSP) [21].
1.4 Monoclonal Antibodies and Emerging Biologics
Biologics have become an indispensable drug in the healthcare toolkit in the last few
decades. mAbs have particularly revolutionized the healthcare industry. The first mAb to be
approved by the Food and Drug Administration (FDA) for human use was a murine mAb called
Muromonab-CD3, which prevents transplanted organ rejection [22, 23]. Muromonab is an IgG-2
isotype mAb approved in 1986 [24]. Nebacumab which is an IgM isotype is indicated for the
treatment of sepsis by targeting endotoxins and was the first mAb to be approved by the
European regulatory agency [24].
Since 2016, about ten mAbs have received regulatory approval in the USA, Europe, and
Japan annually [25]. More than 570 antibody therapeutics were undergoing clinical trial phases
in 2019 [26]. Antibody-related therapeutics include bispecific antibodies (bsAbs), Fc-fusion
proteins, and antibody-drug conjugates (ADCs) [24]. mAbs are invaluable in oncology, treatment
of autoimmune disorders, transplanted organ rejection, nervous system disorders, COVID-19,
and other indications. Commercial-scale mAb production has provided relief to sick patients
globally; however, the cost of care is still a cause of concern. An anti-SARS COV-2 mAb
cocktail regimen by Regeneron costs over $3000 per dose.
4

The mAb industry grossed over $154 billion in 2020 [27, 28]. Some blockbuster mAbs
like Humira (Adalimumab), Herceptin (Trastuzumab), Keytruda (Pembrolizumab), and Rituxan
(Rituximab) each generate over $6 billion in annual sales [29]. The high cost of these mAbs can
be attributed to the extensive research and clinical trials required for their development, among
other factors. Due to the rise of generic biologics or biosimilars in emerging economies,
industrial demand for reduced production costs is pertinent [30, 31]. The biosimilar industry is
angling for a share of the profitable market as older, successful mAbs face patent expirations
[30]. For the established brand name mAb manufacturers to ward off competition from generics,
much research is needed to optimize the upstream and downstream production process.
Companies have also adapted by researching new therapeutic indications for their blockbuster
mAbs or application as antibody-drug conjugates [31].
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2.0 Process- and Product-Related Foulants in Virus Filtration
* This chapter is adapted from a published paper: Isu, S., Qian, X., Zydney, A. L., &
Wickramasinghe, S. R. (2022). Process- and Product-Related Foulants in Virus Filtration.
Bioengineering, 9(4), 155. doi:10.3390/bioengineering9040155.
Abstract
Regulatory authorities place stringent guidelines on the removal of contaminants during
the manufacture of biopharmaceutical products. Monoclonal antibodies, Fc-fusion proteins, and
other mammalian cell-derived biotherapeutics are heterogeneous molecules that are validated
based on the production process and not on molecular homogeneity. Validation of clearance of
potential contamination by viruses is a major challenge during the downstream purification of
these therapeutics. Virus filtration is a single-use, size-based separation process in which the
contaminating virus particles are retained while the therapeutic molecules pass through the
membrane pores. Virus filtration is routinely used as part of the overall virus clearance strategy.
Compromised performance of virus filters due to membrane fouling, low throughput, and
reduced viral clearance is of considerable industrial significance and is frequently a major
challenge. This review shows how components generated during cell culture, contaminants, and
product variants can affect virus filtration of mammalian cell-derived biologics. Cell culturederived foulants include host cell proteins, proteases, and endotoxins. We also provide mitigation
measures for each potential foulant.
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2.1 Introduction
A virus filtration step is frequently included to provide a robust size-based clearance of
both enveloped and non-enveloped viruses during the manufacture of mammalian cell-derived
biotherapeutics, such as monoclonal antibodies (mAbs) and Fc-fusion proteins [1, 2]. Before
approval of new therapeutics, regulatory agencies such as the US Food and Drug Administration
(FDA) require validation of adequate virus clearance [3]. Consequently, unit operations are
added to the purification train to ensure high levels of virus clearance [4].
Virus filtration uses large pore size ultrafiltration membranes to retain any contaminating
virus particles while recovering the virus-free product in the permeate. Unlike ultrafiltration
operations, the performance criteria for virus filters are far stricter [5]. Typically, around 95%
product recovery is required while maintaining at least 1000-fold virus clearance [1].
Virus filtration is different from typical pressure-driven membrane filtration processes as
the filter is designed to obtain high levels of removal of potential virus contaminants. Further, as
it is impractical to validate that there is zero carryover of any trapped virus particles, reuse of the
virus filter is impossible. Consequently, these are single-use devices. Virus filters are typically
run in normal flow (dead end) mode rather than tangential flow mode used for protein
ultrafiltration since normal flow is less complex and requires only a single pump.
Table 2.1 lists a range of mammalian cell-derived biotherapeutics that have been
approved by the food and drug administration in the last three decades. This is a non-exhaustive
list showing the various classes and drug names. Mammalian cells used for the expression of
recent FDA-approved monoclonal antibodies include Chinese hamster ovary (CHO) cells and
murine myeloma cells (Sp2/0, NS0), among others [6, 7].
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Table 2.1: Examples of Approved Chinese Hamster Ovary (CHO) Cell-derived Biotherapeutics.
(Non-exhaustive List Compiled from Publicly Available Resources,
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process), US
Food and Drug Administration, European Medicines Agency [16].

Drug classification

Monoclonal
antibodies

Fc-fusion proteins

Cytokines

Examples

First approval by
FDA

Manufacturer

Pembrolizumab

2014

Merck

Nivolumab

2014

Bristol-Myers Squibb

Aducanumab

2021

Biogen

Avelumab

2017

EMD Serono

Omalizumab

2003

Genentech

Adalimumab

2002

Abbvie

Tezepelumab-ekko

2021

Amgen / AstraZeneca

Abatacept

2021

Bristol-Myers Squibb

Aflibercept

2011

Regeneron

Alefacept

2003

Biogen

Etanercept

1998

Amgen

Rilonacept

2008

Regeneron

Darbepoetin alfa

2011

Amgen

Interferon beta-1a

2003

Biogen

Epoetin alfa

2011

Amgen
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Table 2.1 (continued): Examples of Approved Chinese Hamster Ovary (CHO) Cell-derived
Biotherapeutics. (Non-exhaustive List Compiled from Publicly Available Resources,
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process), US
Food and Drug Administration, European Medicines Agency [16].

Drug classification

Enzymes

Hormones

Examples

First approval by
FDA

Manufacturer

Agalsidase beta

2003

Genzyme

Human DNase

1993

Genentech

Laronidase

2003

BioMarin

Tenecteplase

2000

Genentech

Choriogonadotropin alfa

2000

EMD Serono

Follitropin alfa

2004

EMD Serono

Osteogenic protein-1

2001

Stryker Biotech

Thyrotropin alfa

1998

Genzyme

The performance of virus filters is measured in terms of product recovery, log reduction
value (LRV) of the virus (defined as the logarithm base 10 of the ratio of the virus concentration
in the feed to that in the permeate), and the productivity of the filter. Productivity is typically
expressed as the volume of feed that can be processed per membrane area (L/m2) before the
filtrate flux has decreased to unacceptably low levels (for operation at constant transmembrane
pressure). Since biopharmaceutical manufacturing operations are still essentially batch processes,
the virus filter is often sized such that the entire batch can be processed in one shift.
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Frequently, identifying a virus filter that meets the three performance requirements:
product recovery, LRV, and productivity is challenging and highly dependent on the feed stream
and membrane properties. As the virus filtration step is located towards the end of the
purification train, the product is highly purified and moderately concentrated [1]. Membrane
fouling, which leads to compromised performance, is typically due to the product- and processrelated foulants rather than any rejected virus particles [1]. The concentration of virus particles in
any process will be orders of magnitude less than that for the product.
Virus filtration membranes are sometimes designed with a reverse asymmetric structure
to improve the removal of impurities and foulants [9]. In this case, the barrier layer faces away
(downstream) while the more open support layer faces towards the feed stream [10]. The support
layer can act as an inline prefilter that traps larger foulants and protects the tight barrier layer
[11]. However, essentially symmetric membranes are also used industrially. The unique
requirements of virus filtration are different from typical pressure-driven membrane separation
processes such as ultrafiltration. Identifying and sizing an appropriate virus filter is often
particularly challenging.
This review describes a typical ‘platform process’ for the downstream purification of
biopharmaceutical products. First, the location of the virus filtration step in the downstream
processing workflow is identified. Next, the major commercially available virus filters are
summarized. The remaining sections of this review highlight various impurities and foulants that
could lead to fouling and compromised performance during virus filtration of mammalian cellderived biologics. Inline virus prefilters that are frequently used to remove product-related
aggregates are also discussed. The review ends with a discussion of future trends in the
development of virus filters.
13

2.2 Downstream Processing
2.2.1 Platform Processes
Biopharmaceutical manufacturing processes can be divided into two main processing
trains: upstream cell culture operations and downstream purification processes. Various
bioreactor configurations are used to produce the cells that express the product of interest
(mAbs, enzymes, Fc-fusion proteins, or hormones). Removing particulate matter such
as cells and cell debris occurs at the interface between upstream and downstream unit
operations. These bioreactor clarification operations are sometimes referred to as midstream
processes [12, 13].
Figure 2.1 is a typical 'platform' process for the downstream purification of monoclonal
antibodies. The first unit operation is typically an affinity chromatography capture step using
protein A (resin-based chromatography) [14]. Affinity interaction is a specific interaction based
on both the topological fit and a combination of electrostatic, hydrophobic, and hydrogenbonding interactions [15]. Antibody elution from the protein A column is done at low pH,
making it convenient to include a low pH hold for virus inactivation.
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Figure 2.1: Downstream Purification of Mammalian Cell-derived Biotherapeutics.

Frequently two polishing steps are used to remove the remaining impurities and product
variants/aggregates [16]. Resin- or membrane-based chromatography (ion exchange or
hydrophobic interaction chromatography) is frequently used. The polishing steps remove
impurities such as DNA, host cell proteins (HCP), and product aggregates [1]. Typically, all
streams and buffers which enter the purification process are passed through sterilizing grade
(0.2-μm pore size) filters to reduce bioburden.
As shown in Figure 2.1, the virus filtration step is typically located near the end of the
purification train. The product is relatively concentrated and highly purified. High product
concentrations can lead to compromised performance due to product aggregation and increased
adsorption to the virus filter membrane. A final ultrafiltration /diafiltration step is used to
concentrate the product and place it in the formulation buffer needed for stability during
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shipping/storage and delivery to the patient. The final 0.2-µm pore size filter is used to ensure
sterility of the product and is often done as part of the final fill-finish operation.
2.2.2 Viruses, Virus Clearance, and Virus Filters
Many mammalian cell lines produce endogenous retrovirus-like particles [1]. These
particles are typically around 80-100 nm in size. Clearance can be achieved by inactivation and
physical removal from the process stream [11, 17, 18]. During purification, manufacturers of
mammalian cell-derived biotherapeutics must demonstrate that the process will yield a final
product containing no more than one virus particle in a million doses. Estimates of the number of
virus particles in a single dose equivalent from the bioreactor could be as high as 1010-1015
retrovirus-like particles per mL [1].
Removal of adventitious viruses such as parvovirus is also required. These much smaller
viruses are around 20 nm in size. In the past, filters targeted for retrovirus and parvovirus
removal were included in the purification train [3]. Recent studies show that virus clearance
filters designed to provide clearance of smaller parvovirus can be used to clear much larger
retroviruses simultaneously [19].
Table 2.2 shows some viruses that are employed for validation studies in
biomanufacturing. The enveloped viruses are typically bigger than the non-enveloped viruses.
Virus filters constitute the last line of defense to guarantee the safety of intravenously-delivered
biologics and, therefore, these must be validated with the smallest possible viruses (nonenveloped viruses). Parvoviruses are commonly used.
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Table 2.2: Some Common Viruses Used for Validation Studies in Biomanufacturing [20].
Name of Virus

Diameter (nm)

Animal parvoviruses (non-enveloped DNA viruses, bovine, canine, or porcine)

18–24

Poliovirus (picornavirus, non-enveloped RNA virus)

25–30

Encephalomyocarditis virus (EMC, picornavirus, non-enveloped RNA virus)

25–30

Feline calicivirus (calicivirus, non-enveloped RNA virus)

35–39

Bovine viral diarrhea virus (BVDV, flavivirus, enveloped RNA virus)

40–60

SV40 (simian vacuolating virus 40, polyomavirus, non-enveloped DNA virus)

45–55

Sindbis virus (togavirus, enveloped RNA virus)

60–70

Reovirus (non-enveloped RNA virus)

60–80

Herpes simplex virus (HSV, herpesviridae, enveloped DNA virus)
Pseudorabies virus (PRV, herpesviridae, enveloped DNA virus)

150
120–200

Adventitious virus contamination is a concern in the manufacture of biologics. Validation
of virus clearance is shown by conducting scale-down testing [21]. The feed is spiked with
model virus particles, and clearance in the product stream is determined. Minute virus of mice
(MVM, mouse parvovirus) is often used to validate adventitious virus clearance. The FDA
requires at least two orthogonal steps with different mechanisms of action for validation of viral
clearance with the required level of virus clearance for the process, determined by summing the
clearances obtained from the individual unit operations [1].
Virus filtration uses porous polymeric membranes in normal flow mode [11, 22, 23]. The
predominant mechanism of action for virus filters is size exclusion [11]. The difference in
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hydrodynamic diameter between a protein product and MVM is often less than two-fold [5].
Today, virus filters are a critical component of the overall virus clearance strategy [11].
Virus filter materials are typically hydrophilic [24], preventing hydrophobic biomolecules
from significantly fouling the membrane through adsorptive mechanisms. As shown in Table
2.3, virus filter membrane materials include hydrophilic cuprammonium regenerated cellulose,
hydrophilic / surface-modified polyethersulfone, and hydrophilic acrylate-modified
polyvinylidene difluoride [24].
The latter two materials are hydrophilized to minimize fouling by adsorption and
maximize flux during virus filtration. While the membrane should be biocompatible, nonfouling, and minimize adsorption on the membrane surface, it is also essential that the membrane
is robust and dimensionally stable to ensure the required level of virus clearance.
These virus filters are typically designed to ensure that only monomeric biomolecules
with a hydrodynamic diameter less than 20 nm can pass through the size cutoff pores. Much
research is needed to understand how a multidomain, anisotropic mAb with varied surface
moieties interacts with virus filtration membranes, prefilters, and other product monomers [25].
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Table 2.3: Commercially Available Virus Filters [1, 24, 26]. Asahi Kasei Bioprocess is a Part of
the Asahi Kasei Group; MilliporeSigma is a Subsidiary of Merck KGaA.

Filter

Manufacturer

Planova 15N,

Asahi Kasei

20N
Planova 35N
Planova

Asahi Kasei
Asahi Kasei

BioEX
Viresolve

MilliporeSigma

Membrane

Configuration

Comments

Regenerated

Asymmetric single-

Parvovirus filter

cellulose

layer hollow fibers

Regenerated

Asymmetric single-

cellulose

layer hollow fibers

Hydrophilized

Asymmetric single-

PVDF

layer hollow fibers

material

Parvovirus filter

Polyethersulfone Asymmetric triple-layer Retrovirus filter

NFR
Viresolve Pro

Retrovirus filter

pleated sheets
MilliporeSigma

Polyethersulfone

Asymmetric double- Parvovirus filter
layer flat sheets

Pegasus SV4
Ultipor VF

Pall Corporation
Pall Corporation

DV20
Ultipor VF

Pall Corporation

DV50
Virosart HC

Sartorius AG

Hydrophilized

Symmetric double-

PVDF

layer pleated sheets

Hydrophilized

Symmetric double-

PVDF

layer pleated sheets

Hydrophilized

Symmetric double-

PVDF

layer pleated sheets

Polyethersulfone

Parvovirus filter
Parvovirus filter
Retrovirus filter

Asymmetric double- Parvovirus filter
layer pleated sheets

Virosart HF

Sartorius AG

Modified

Asymmetric single-

polyethersulfone

layer hollow fibers

Parvovirus filter

Table 2.3 is a non-exhaustive list showing commercially available virus filters and
material configurations.
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Virus filter membrane fouling is a significant challenge [23, 27, 28]. Fouling can
compromise virus clearance and reduce membrane productivity (product recovered per
membrane surface area) [29]. Fouling is often due to product variants because of the high
product purity before virus filtration and the high product concentration compared to the spiked
virus concentration [1, 30].
Recent studies focusing on virus filtration of mAbs showed that membrane performance
depends on the mAb properties (pI, hydrophobicity, net charge, dipole moment, oligomericity),
buffer conditions, membrane material, and operating pressure [23, 31, 32]. Buffer excipients
such as arginine and lysine can stabilize mAbs and reduce fouling propensities [33]. Excipients
such as histidine, arginine, and lysine can reduce reversible self-association of mAbs to varying
degrees [34]. Reversible self-association is often concentration-dependent [23, 34, 35].
2.3 Virus Filter Foulants
This section describes the major classes of foulants in virus filtration. This includes
irreversible and reversible product aggregates and minor product variants that differ in their
charge or hydrophobicity. Product variants arise because mammalian cell-derived
biotherapeutics are heterogeneous. The product is defined based on the production process and
not on a single molecular species. Product variants with different post-translational modifications
can have different hydrophobicity, charge, and conformations. If present, HCP, proteases, and
nucleic acids can also foul the virus filter.
2.3.1

Monoclonal Antibody Aggregates
Aggregation is a typical occurrence with mAbs and other therapeutic proteins. Several

pathways have been proposed to describe the aggregation of proteins. They include
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agglomeration of monomers in their native states, aggregation of conformationally altered or
chemically modified monomers, nucleation, and surface-induced aggregation [36-38].
Significant attention has been placed on non-native monomer aggregation since exposed
hydrophobic moieties tend to self-associate [36]. Some surfactants, osmolytes, and chaotropes
induce aggregation because they denature the monomeric product, exposing more of the
hydrophobic core and distorting the surface charge distribution [39]. Physical and biochemical
events can also induce product degradation through enzymatic and non-enzymatic processes
such as shock, light, and oxidation [40].
Physical or chemical perturbations that put a strain on the native conformation of
biotherapeutic proteins such as mAbs can result in clipping or aggregation [41]. Such conditions
include the presence of chaotropic chemical species, pH swings [42], shock, mechanical stress,
increased concentration, and large temperature fluctuation [36, 43, 44]. The size, surface charge,
and hydrophobicity of a mAb multimer will differ from that of the native monomer.
Interfacial damage can also affect the stability of a product monomer, especially at the
air-liquid interface, which induces nucleation and aggregation [45]. Surface tension and physical
adsorption on solid surfaces also lead to conformational changes [36, 46, 47]. Freezing and
thawing of the product induce more aggressive fouling of virus filters [1, 22, 48]. Freeze-thawinduced aggregation is due to conformational changes at the ice-liquid interface and by freeze
concentration [36, 46, 49].
Reversible aggregates are usually a precursor to nucleation [50], followed by irreversible
aggregation as the aggregates increase in size [51, 52]. As buffer ionic strength increases,
electrostatic repulsion between the mAbs decreases, whereas hydrophobic attraction between the
mAb increases, often leading to product aggregation [46]. Aggregation and precipitation occur
21

most easily at the product's isoelectric point (pI) due to reduced electrostatic repulsion between
individual product molecules [53, 54].
2.3.1.1 Reversible Aggregates
Aggregation can occur through different pathways resulting in aggregates that are
reversible or non-reversible [36, 39]. mAb oligomers such as dimers, trimers, and tetramers are
typically reversible [36, 37]. Reversible aggregates are known as soluble aggregates, and the
associated product monomers are not significantly denatured. Soluble aggregates are caused by
interactions between product molecules via hydrogen bonding, electrostatic, or van der Waals
forces [39, 55]. These soluble aggregates could foul virus filters if their size exceeds the 20 nm
size cutoff of most parvovirus filters.
Rayfield et al. [27] investigated the impact of mAb properties on virus filter filterability
and showed that aggregates bigger than 17 nm were correlated to the flux decline during virus
filtration [1, 27]. Monoclonal antibodies typically have a hydrodynamic diameter of 9-12 nm;
thus, the small oligomers can be 20 nm to as much as 50 nm in diameter. Other studies have
shown that freeze-thawing of mAbs may not cause aggregation in significant amounts detectable
by size exclusion chromatography due to the relatively small diameters of potential aggregates
formed [48, 56, 57].
2.3.1.2 Irreversible Aggregates
When product dimers and trimers undergo further aggregation, they attain a critical mass
where the aggregate can no longer remain soluble. These large aggregates then precipitate out of
the solution [36]. The precipitates become visible and show increased turbidity and cloudiness.
These large aggregates are known as irreversible aggregates. Large, insoluble aggregates have an
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increased propensity to foul the separation-active layer during virus filtration. Barnard et al.
investigated the principal foulant of freeze-thawed mAb solutions and found that the freeze-thaw
process could induce the formation of large aggregates (>1 μm) [48]. The use of 0.1 or 0.2 µm
pore size prefilters can marginally reduce virus filter fouling by removing large aggregates.
Irreversible aggregation is prevalent with denatured product monomers [37, 39].
Chemical degradation, such as oxidation and deamidation, alters the surface charge of product
monomers and affects colloidal stability [37]. Irreversible aggregation of mAbs results in product
loss, although low levels of aggregation (<1%) can cause a significant increase in filter fouling.
Hawe et al. studied mAb aggregates formed during freeze-thaw and heat-induced thermal stress
[47]. Other studies show that heat denatures mAbs and leads to irreversible mAb aggregation
[37, 39].
2.3.2 Host Cell Proteins (HCP), Proteases, and Nucleic Acids
HCP features significantly in the downstream processing of protein-based therapeutics
[31]. HCP includes proteins, enzymes, and co-enzymes which emanate from the host cell used
for product expression [58]. It is essential to remove HCP from therapeutic proteins because they
can elicit an immune response. There are regulatory requirements for robust HCP removal before
clinical trials of drug candidates to prevent the development of anti-CHO antibodies by
volunteers [59, 60]. Some HCP can coelute with the mAbs through polishing and purification
steps either due to binding to the resin or association with the mAb product [58, 61-63]. Zhang et
al. identified over 500 HCP in a cell culture sample and tracked their fate through downstream
processing unit operations [64]. After studying nine different mAbs, they determined that actin
and clusterin were most abundant in protein A eluates [64].
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Enzymatic HCP (host cell proteases) can clip or denature product monomers, expose
hydrophobic residues, and charged moieties, and alter the product's biophysical properties.
Denatured product monomers with exposed residues induce virus filter fouling by adsorptive
processes in addition to mAb-mAb and mAb-HCP association. Host cell proteases have been
reported to result in the fragmentation of mAb products, with increased susceptibility to
nucleation and aggregation [65]. However, proteases themselves are probably not principal
foulants of virus filters since virus filtration occurs towards the end of downstream processing,
where only trace amounts of non-mAb impurities may be detected [18, 66].
HCP diminishes the biotherapeutic quality of biotherapeutic products and increases
downstream processing costs. If HCP is not sufficiently removed, it could potentially induce flux
decay during virus filtration. HCP has a range of biophysical properties, such as pI (2-11) and
mass (10-200 kDa) which can be used to separate the HCP from the biotherapeutic [67, 68].
Protein A chromatography significantly reduces HCP in the mAb product due to high selectivity
for the Fc region of mAbs [61]. Several studies reported that the propensity of different HCPs to
bind and coelute with mAbs from protein A columns vary from mAb to mAb [62, 69].
Problematic HCP are many and include lipoprotein lipase, nidogen-1, clusterin, histones,
keratins, phospholipases, ribosomal proteins, and serine proteases [67].
2.3.3 Endotoxins
Endotoxins or lipopolysaccharides (LPS) are contaminants that can enter the process
through growth media or other cell culture additives used in mammalian cell cultures. LPS are
produced by gram-negative bacteria, commonly used in recombinant DNA production [70-72].
Endotoxins are commonly found as contaminants in mammalian cell-derived therapeutics [73].
LPS are complex molecular conjugates of an amphiphilic component (lipid A) and a polar
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polysaccharide component [71, 72]. The isoelectric point of LPS ranges from 1 to 4 [68]. LPS
removal techniques that have been reported include two-phase extraction, affinity
chromatography, and ion-exchange chromatography [72].
LPS has been reported to have a high affinity for some biotherapeutic proteins [73]. LPS
and therapeutic proteins can form micellar aggregates, complicating the removal process and
potentially carrying over into the virus filtration step [72, 74]. Phosphorylated moieties of LPS
electrostatically bind with the carboxyl moieties of amino acids in the biologic of interest [72,
74]. Solutions of 0.5 M arginine have been shown to promote LPS clearance during polishing
steps [74].
LPS have molecular masses ranging from 3 - 40 kDa, which varies due to their
polysaccharide chain lengths [68, 72]. Endotoxins can coelute with mAbs and Fc-fusion proteins
from protein A resins by molecular conjugation through hydrophobic and electrostatic
interactions, ultimately causing problems during virus filtration. Endotoxin-contaminated mAb
streams have an increased propensity to cause virus filter fouling. Removal of endotoxins
through ion exchange polishing steps increases the virus filtration capacity of virus filters.
2.3.4 Product-Mediated Foulants
Product-mediated foulants are mAb species that have a higher propensity to induce
fouling of the virus filter, as shown by the illustration in Figure 2.2 below.
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Figure 2.2: Fouling of Virus Filtration Membranes Induced by Product-related Foulants (mAb
Variants)
Figure 2.2 shows five variants of the mAb present in the feed and color-coded red, grey,
blue, green, and yellow. The red and green color-coded foulants induce fouling on the virus
filter. In contrast, the black, yellow, and green mAb variants are collected in the permeate.
2.3.4.1 Charge Variants
The charge variant profile is a critical quality attribute of mAbs,[75] and Fc-fusion
proteins. Charge variants in mAbs can result from post-translational modifications (PTMs), such
as deamidation of asparagine, C-terminal lysine variants, and glycosylation [76-79]. Glycans are
mostly polar, hydrophilic oligosaccharides that can induce micro-differences in the surface
charge of a glycoprotein [80]. Negatively charged glycans incorporating phosphorylated
mannose and sialic acid can introduce micro-heterogeneities [80]. Charge heterogeneity is
observed in isoelectric focusing electropherograms of most glycoproteins [76]. Acidic and basic
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variants of glycoproteins such as mAbs and Fc-fusion proteins can have different glycan profiles
[81, 82]. Meyer et al.72 reported that specific charge variants of a mAb candidate were
aggregation-prone. Acidic variants of this mAb showed increased hydrophobicity [80].
The net charge and surface charge distribution of glycoproteins change with buffer pH
[78, 83, 84]. The pI of a protein is the pH value at which the net charge is zero [53]. For most
mAbs, the pI ranges from 6.5 to 9.5 [53]. There is more biochemical variability with Fc-fusion
proteins. A protein will be net negatively charged when the buffer pH is above the pI and
positively charged when the buffer pH is below the pI [85]. Exposed surface residues on a
glycoprotein can become protonated or deprotonated depending on the buffer pH, thereby
inducing localized charged groups [86]. Charged moieties due to glycosylation, phosphorylation,
and other PTMs affect the net charge of glycoproteins and their interactions with other product
monomers and virus filtration membranes [85].
2.3.4.2 Denatured variants
Hydrophobic interaction is the preferential association of non-polar residues in aqueous
media [87]. Amino acids with non-polar side chains are typically hydrophobic, e.g., valine,
leucine, proline, and tryptophan. Polar amino acids such as arginine impart hydrophilic attributes
to glycoproteins [88]. When hydrophobic amino acids are surface-exposed on a glycoprotein,
hydrophobicity increases. Hydrophobic amino acids tend to be buried in the globular core of
most glycoproteins. The hydrophobicity of a protein is also affected by the buffer pH and the
protein's charge state [89]. When the buffer pH is close to the pI of the protein, the protein is the
most hydrophobic [87]. Denaturation and unfolding of glycoproteins can lead to variants with a
higher fouling propensity on virus filters.
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The glycan appendages of glycoproteins also contribute to the final stable conformation,
and glycan variation can introduce minor hydrophobicity variations. Careful handling and mild
changes in formulation conditions will reduce the formation of conformational variants, which
could foul virus filters or induce product aggregation.
2.3.4.3 Sequence Variants
Monoclonal antibodies and Fc-fusion proteins consist of amino acids in specific
sequences that form secondary, tertiary, and quaternary structures. Sequence variants arise due to
genetically unprogrammed amino acid substitutions, omissions, or insertions during biosynthesis
[90]. Sequence variants result in macro-heterogeneities with biomolecular differences from the
desired product [90]. Sequence variants possess different affinities to substrates [91] due to
surface charge and hydrophobicity dissimilarities. The amino acid sequence of a glycoprotein
determines its hydrophobicity, conformation, and charge, amongst other properties [90].
The primary structure (amino acid sequence) of a glycoprotein can determine
intermolecular, monomeric association, and multimerization propensity [51]. Even minor
sequence differences can cause conformational differences leading to product variants with
different biophysical attributes and virus filter fouling propensity. Inadvertent substitution of
hydrophilic amino acids with hydrophobic amino acids or vice versa in the polypeptide sequence
amplifies sequence variants.
2.3.4.4 Microheterogeneity-Induced Product Variants
mAbs, antibody fragments, bispecific antibodies, and Fc-fusion proteins are expressed in
mammalian cells like Chinese Hamster Ovary (CHO) cells for pharmaceutically relevant
glycosylation profiles [15]. Flynn et al. reported that a typical CHO cell culture batch of mAbs
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has three major glycan species present, and they are G0F, G1F, and G2F [92]. These three
dominant glycan structures are dependent on cell lineage and culture parameters [93]. E. coli
expresses mostly insoluble, non-glycosylated variants [77]. Hybridomas offer a rapid expression
template for initial product manufacture [15, 94, 95].
During cell culture and harvesting operations, expressed glycoproteins are usually not
uniformly glycosylated [40, 96, 97]. Glycoproteins are expressed with a range of glycosylation
profiles depending on cell culture conditions [98-103]. Micro-heterogeneity of glycoproteins can
occur as a result of differences in glycosylation and other post-translational modifications.
Variations in appended glycans introduce charge heterogeneity to the product monomer and
determine the glycoprotein's native fold state, aggregate susceptibility, and stability [104-107].
These product variants can affect the performance of virus filters.
Glycans are hydrophilic oligosaccharide moieties typically appended to glycoproteins in
the cell during glycoprotein synthesis [108]. Glycans assist in the proper folding of the
polypeptide chain before product secretion [76, 96, 109]. Most therapeutic proteins are
glycoproteins. Glycoforms of protein products introduce structural heterogeneity, which affects
their affinity to substrates, their stability, and other physicochemical characteristics of these
therapeutic proteins [108, 110, 111]. Even in the same cell culture batch, a range of glycoforms
occurs [108, 112, 113]. Glycoforms occur due to skipped glycosylation sites on the glycoprotein
or differences in the structure of appended glycans [96].
Glycan type and abundance can alter the product's biophysical properties. Several studies
have looked at the stability of different mAb glycoforms. These results show that aggregation is
more prevalent in unglycosylated mAbs since glycans modulate aggregation [108, 114].
Furthermore, a study showed that in terms of physical stability between pH 4 - 6, di29

glycosylated IgG1 type mAbs were the most stable, and mono-glycosylated IgG1 was the least
stable [115]. Post-translational modification can strongly affect the pI of a glycoprotein [76,
108]. Variations in the pIs of product variants would affect hydrophobic and electrostatic
interactions.
2.4 Mitigation of virus filter fouling
2.4.1 Prefiltration before virus filtration
Even though the support structure of the virus filter can function as an inline prefilter,
significant fouling is often observed due to the product and process-related foulants listed above
that could be present in the feed stream. Standard practice involves the inclusion of a virus
prefilter to remove these contaminants. Virus prefilters may rely on one or more mechanisms of
action for the removal of foulants. The use of prefilters upstream of a virus filter increases
permeate flux to the degree allowed by the biotherapeutic product properties, prefilter material,
and buffer conditions [1]. The mechanisms and conditions for foulant capture are different for
different prefilters [1].
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Table 2.4: Commercially Available Prefilters, Modes of Action, and Manufacturers [24]
Prefilter
Planova 75N
Bottle top 0.1 / 0.2
µm
Pegasus Protect
Sartobind Q

Material
Regenerated cellulose
Polyethersulfone
Nylon
Quaternary
ammonium ligands

Mechanism of action
Size exclusion, removal of small
aggregates

Manufacturer
Asahi Kasei

Size exclusion, removal of large

ThermoFisher

aggregates

Scientific

Size exclusion, removal of large
aggregates

Pall

Anion exchange

Sartorius AG

Sartobind S

Sulfonic acid ligands

Cation exchange

Sartorius AG

Sartobind phenyl

Phenyl ligands

Hydrophobic interaction

Sartorius AG

Viresolve Pro
Shield
Viresolve Pro
Shield H

Surface modified PES
Surface modified PES

Size exclusion, ion exchange
(cation)
Size exclusion, hydrophobic
interaction

MilliporeSigma
MilliporeSigma

Diatomaceous earth, Cation exchange, size exclusion,
Viresolve Prefilter cellulose fibers, and a
cationic imine binder

hydrophobic interaction, ion

MilliporeSigma

exchange,

Table 2.4 above shows a non-exhaustive list of common prefilters used to capture
foulants and mitigate fouling during downstream virus filtration. Size exclusion prefilters such as
the 0.1 and 0.2-micron filters remove aggregates large than the respective size cutoff of the
prefilters. Ion exchange prefilters are more effective at low conductivity due to the reduction in
electrostatic shielding when the solution pH is close to the pI of the biologic. If the solution pH is
1-2 units away from the pI of the biomolecules, then an ionic strength increase is required to
enable operation in the flowthrough mode
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The Sartobind S membrane is typically used as a prefilter before virus filtration. Sulfonic
acid ligands are negatively charged in aqueous solutions and preferentially bind more positively
charged species in the feed stream. Process development teams typically optimize buffer
parameters to ensure the biotherapeutic flows through cation exchange membranes while
aggregates and the most basic molecular variants are captured by the cation exchange prefilter
[116]. The Sartobind Q membrane is an anion exchange membrane with positively charged
quaternary ammonium ligands. Ion exchange membranes are used as adsorptive prefilters that
remove aggregates and aggregation-prone charged variants of a biotherapeutic product [80].
Wickramasinghe et al. opined that trace amounts of aggregates that have a diameter less
than 50 nm play a significant role in virus filtration membrane fouling [1]. These small
aggregates with diameters less than 50 nm cannot be removed by 0.1-μm or 0.2-μm size
exclusion filters but can block the virus filter pores. Virus filtration membranes typically have a
pore size around 20 nm at the separation-active layer.
Soluble aggregates (20 – 50 nm) can be removed using adsorptive prefilters (cation
exchange, anion exchange, multimodal) to prevent fouling of virus filters. Adsorptive prefilters
have been shown to bind aggregates, thereby reducing subsequent fouling of virus filters.
Adsorptive prefilters work well for product oligomers in the 600 - 1500 kDa range, which cannot
be removed by 0.2-µm size-exclusion prefilters. Ion-exchange prefilters have shown great
potential in clearing aggregates for effective downstream processing operations [117].
Endotoxins can be removed using hydrophobic prefilters, which bind the phosphorylated
lipid moiety, or using anion exchange prefilters to capture the polysaccharide moiety [71, 74,
118]. Anion exchange membranes work well for endotoxin removal due to the positively charged
ligands binding with the negatively charged endotoxin (isoelectric point = 1 - 4).
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Hydrophobic prefilters require a moderate/high salt content (ionic strength) to reduce the
product's solvation layer enabling exposed hydrophobic patches to adsorb on the hydrophobic
prefilter. Hydrophobic interaction prefilters can be effective in removing product variants with
different hydrophobicity as well as some of the more hydrophobic product aggregates.
Ion exchange prefilters are helpful in the downstream removal of HCPs due to the pI
difference between mAbs and most HCPs. DNA is strongly negatively charged in an aqueous
solution and can be effectively removed using anion exchange membranes during polishing
operations [19, 118].
Multimodal prefilters are helpful for filtering out foulants that cannot be removed by ion
exchange, size exclusion, or hydrophobic interaction-based prefilters alone. These multimodal
prefilters include the three prefilters from MilliporeSigma, as shown in Table 2.4.
2.4.2 Mitigation of virus filter fouling using process parameters
MAb properties are highly dependent on the buffer conditions and excipients that are part
of the formulation. Excipients are non-drug substance components of the formulation. During
high throughput screening of mAbs for optimum buffer conditions, a specific buffer type and
composition may be found to inhibit aggregation and mitigate fouling of virus filters. Phosphate,
acetate, and tris buffers may work for some biomolecules, while viscosity inhibiting buffers may
be preferred for highly concentrated mAbs. Arginine reduces mAb monomeric self-association,
nonspecific membrane interactions, and mAb aggregation [119]. Excipients such as histidine and
arginine marginally improve the stability of monomeric species during formulation [37, 120].
These excipients can result in cost reduction for virus filter consumables but may require further
removal before drug substance delivery to the patient.
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2.5 Outlook
Achieving the high levels of virus clearance for mammalian cell-derived biotherapeutics
will continue to be a challenge. There is a continuing need for better virus filters that maximize
productivity, flux, and LRV for batch processes. As biomanufacturing moves towards continuous
manufacturing platforms, there will be a need to develop new virus filters. Unlike current virus
filters, which are designed to process a product batch in one shift, in continuous
biomanufacturing, the virus filter will be run for much longer times and likely at much lower
filtrate flux/transmembrane pressure. Further development of virus filters for continuous
operations will be needed.
There is a growing demand for virus particles and virus-like particle-based vectors to
deliver gene therapies and vaccines. Virus particle-based delivery systems such as attenuated,
recombinant, infectious, and inactivated virus particles, as well as virus-like particles and even
subunits of virus particles, are highly effective therapeutics. However, downstream purification
of these new therapeutics is challenging [121]. Future virus filter designs will need to be
optimized for these emerging therapeutics.
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3.0 Impact of Prefilter Mechanisms of Action on Virus Filtration of A mAb
3.1 Introduction
Biopharmaceutical manufacturing often consists of a ‘standard’ sequence of unit
operations (platform processes). These unit operations are grouped into two major categories:
upstream and downstream, as shown in Figure 3.1 below. The upstream unit operations include
the cell culture and bioreactor clarification steps [1]. At the same time, downstream purification
processes comprise sequential steps of chromatography, virus filtration, and
ultrafiltration/diafiltration (UF/DF) [1].

Figure 3.1: Flow Chart of a Monoclonal Antibody Production System
Typically, the bioreactor is operated in a batch mode; however, perfusion bioreactors
have become mainstream in recent times. Clarification processes are used to separate
extracellular products (mAbs) and proteins from bulk cellular materials, while protein A columns

44

are used to separate the mAbs from the HCP. Polishing and downstream purification processes
are predominantly batch processes with large industrial and cost footprints and significant
residence times [2, 3].
Polishing steps are mandated by regulatory bodies after protein A affinity
chromatography to eliminate remaining impurities [1]. Impurities can be structural and
biophysical variants of the mAb, such as oligomers, denatured mAbs, and host cell proteins.
Cation exchange, anion exchange, and hydrophobic interaction chromatography (HIC) are
typically used as chromatographic polishing steps that further purify the mAb before virus
filtration.
Two polishing steps are shown in Figure 3.1, Hydrophobic interaction chromatography
(HIC) and ion-exchange chromatography (comprising cation exchange chromatography and
anion exchange chromatography). HIC polishing removes aggregates and denatured proteins
from the feedstream based on a difference in hydrophobicity in the presence of buffer salts. Ion
exchange membrane adsorbers remove contaminants and aggregates by an adsorptive process
driven by electrostatic interactions in low salt buffers. Polishing with the anion exchange
membranes can also remove viruses due to the pI difference between viruses and mAbs. Ion
exchange membranes generally ensure HCP removal by pI differences between the mAb and
HCP.
The polished product passes to a virus filter before the final formulation. Virus filtration
is mandated for the robust removal of adventitious virus contamination. These single-use virus
filters are typically the most expensive component needed in downstream purification [4].
Protein A columns are expensive but are reusable. Virus filtration works on the size exclusion
principle, where particles 20 nm or larger do not pass the virus filter [5].
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Less expensive mAb biosimilars have resulted in process intensification efforts for costcompetitiveness [6]. Continuous bioprocessing efforts have led to moving bed systems and
counter-current chromatography systems [7]. Pall, GE Healthcare, Semba, Chromacon, and
Novasep are developing continuous downstream processing unit operations [8]. Integrating new
technologies into existing downstream platform processes remains a central challenge [9].
Biologics are mainly produced from mammalian cell cultures [10]. There is always a
likelihood of product contamination by DNA, HCP, proteases, endotoxins, and viruses. mAb and
protein stability are governed by amino acid sequence and post-translational modifications [11],
which influence pI and hydrophobicity and affinity to polishing membranes.
Therapeutic proteins require process validation for safety reasons, including the absence
of virus contaminants from the host cell. Virus removal strategies are robustly implemented and
begin with rigorous quality control testing of source materials and finished products coupled
with multiple virus inactivation/removal unit operations [7, 12]. The manufacture of mAbs
includes several harvesting and orthogonal purification/sterilization steps. Environmental factors
such as pH, temperature, ionic strength, protein concentration, oxygen, and shear forces can
affect filtration performance [13-15].
Ion exchange chromatography is viewed as the gold standard in protein partitioning due
to its excellent robustness and resolution [16]. Ion exchange membranes are most effective when
there is less competition between the biomolecules and buffer ions. This is the case when low
ionic strength buffers are used to constitute the mAb. The pI of mAbs is usually higher than the
pI of HCPs, thereby enabling mAb purification by electrostatic partitioning. Charge
heterogeneity of biologics is a valuable partitioning parameter for anion and cation exchange
membranes or resins [17]. HIC membranes require a moderate/high salt content (ionic strength)
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to reduce the mAb solvation layer enabling exposed hydrophobic patches on foulant species to
adsorb on the HIC ligands.
Prefiltration of mAbs before virus filtration aims to reduce flux decay during virus
filtration by capturing fouling species before virus filtration. Such foulants may include
multimers and denatured mAbs with a high multimerization tendency. Denatured mAbs with
more surface-exposed hydrophobic residues present as monomeric variants to the native-state
mAb monomers and increase fouling tendency through an increased tendency to aggregate.
Aggregates can be categorized as soluble when they are bound by non-covalent forces with a
small number of proteins involved; and insoluble otherwise [18]. Small reversible aggregates
have been largely identified as the principal foulant of virus filters [18-20]. In this work, we seek
to understand the impact of different prefilter types, buffer pH, salt content, and excipients on the
fouling of virus filters.
3.2 Materials and Methods
3.2.1 Materials
Reagents used include tris(hydroxymethyl)aminomethane (biotechnology grade, 99%
purity), Ammonium sulfate (proteomics grade, > 99.5% purity), and Sodium dodecyl sulfate
(biotechnology grade, > 99% purity) sourced from VWR Life Science (Radnor, PA). Sodium
chloride (molecular biology grade > 98% purity), Sodium phosphate monobasic monohydrate
(ACS reagent, > 98% purity), Sodium phosphate dibasic (reagent plus, >99% purity), OmniPur
sodium acetate trihydrate (molecular biology grade, > 99% purity), Glycine (for electrophoresis,
> 99% purity), Acrylamide for synthesis (79-06-1), Acetonitrile (liquid ≥99.8% purity), and
Glacial acetic acid (100% purity) were sourced from MilliporeSigma (Billerica, MA).
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Ultrapure water with a resistivity of 18.2 MΩ was used for buffer formulation.
Recombinant glycosidase (PNGase F, 500 units with 10 u/μl) was sourced from Promega
(Madison, WI). Precision protein plus MW standard and Bromophenol blue indicator, Supelco
(115-39-9) were sourced from Bio-Rad laboratories (Hercules, CA). Dithiothreitol (molecular
biology grade, >99% purity) was sourced from Gold Biotechnology (St. Louis, MO).
10 kDa molecular weight cutoff (MWCO) PES centrifugal filters were sourced from
VWR Life Science (Radnor, PA). Nalgene™ rapid-flow™ sterile single-use bottle top filters
(0.2μm and 0.1μm) were sourced from ThermoFisher Scientific (Waltham, MA). Other selected
prefilters were Planova 75N provided by Asahi Kasei Medical (Tokyo, Japan), Sartobind®
Phenyl nano 3 mL, Sartobind® Q nano 3 mL, 8 mm bed height, and Sartobind® S nano 3 mL, 8
mm bed height provided by Sartorius (Göttingen, Germany). The selected virus filter was
Planova BioEX (membrane surface area 0.0003m2) provided by Asahi Kasei Medical (Tokyo,
Japan).
HiTrap Capto S Impact column (5 ml) was sourced from Cytiva (Marlborough, MA).
TangenX Sius PDn Cassette (30 kDa MWCO, mPES, 0.1 m2) was sourced from Repligen
(Marlborough, MA). SDS MW analysis kit (PN: 390953), Fast glycan labeling and analysis kit
(PN: B94499), CZE rapid charge variant analysis kit (PN: C44790), and Advanced cIEF starter
kit (PN: A80976) were sourced from SCIEX (Redwood City, CA).
3.2.2 Monoclonal Antibody Sample Preparation and Buffer Conditions
mAb B was provided by a biopharmaceutical company and had been processed through
two chromatography polishing steps prior to receival. The isoelectric point (pI) of mAb B was
initially given as 8.0; pI determination by cIEF on receival showed a pI range of 7.1 to 8.0. 250
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ml batches of mAb B (5.4 g/L) were ultrafiltered and diafiltered from the original buffer to a
final formulation of 5 g/L mAb B in 20 mM sodium acetate buffer, 200 mM NaCl (pH 5) with
the same final volume as the initial volume (250 ml). Other portions of mAb B were buffer
exchanged into 20 mM sodium acetate buffer, 200 mM NaCl (pH 8.6 titrated with tris base) at 5
g/L, and 20 mM sodium acetate buffer, with no salt (pH 7.5, titrated with tris base) at 5 g/L. All
mAb B filtration studies were performed at 5 g/L. TangenX Sius PDn Cassette (30 kDa MWCO,
mPES, 0.1 m2) was used for UF/DF.
The mAb stock concentration was measured by UV spectrophotometric analysis at 280
nm using Genesys10 UV Scanning System (Waltham, MA) with VWR quartz spectrophotometer
cell (path length 1 cm; West Chester, PA). mAb concentration and turbidity were determined by
measuring the absorbance at 280 and 340 nm, respectively. Mass balance on the UF/DF mAb
feed and final product resulted in over 95% mAb recovery, with the feed concentration dropping
from 5.4 g/L to 5 g/L in the retentate.
Buffer exchange was performed by ultrafiltration and diafiltration (UF/DF) of 5 g/L mAb
B in five diafiltration volumes using a TangenX Sius™ PDn HyStream 30kDa tangential flow
filtration (TFF) Cassette (Shrewsbury, MA). Buffer pH and conductivity were measured using
Orion Star™ A215 pH/conductivity benchtop multiparameter meter from ThermoFisher
Scientific (Waltham, MA). mAb fractions were immediately used for prefiltration or virus
filtration following buffer exchange or stored at 4oC for one week. mAbs were stored for
extended periods at -80oC.
Sartobind membrane adsorbers are typically used for mAb polishing; however, we
adopted them as adsorptive prefilters post mAb polishing. HIC prefiltration was performed using
the Sartobind phenyl 3 ml membrane. At the same time, anion and cation exchange-based
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prefiltration was performed using the Sartobind Q and Sartobind S, respectively. Prefiltration of
mAb B was not performed in line with the virus filter. Figure 3.2 below shows the workflow for
prefiltration and virus filtration.

Figure 3.2: Decoupled Prefiltration and Virus Filtration Workflow (Prefiltration was not Inline)
In the above workflow, the mAb was filtered with a 0.2-micron PES filter before
adsorptive prefiltration using the requisite prefilter. Buffer formulations were selected such that
the flowthrough fraction was the mAb product and was subsequently filtered with the BioEX
virus filter. Before mAb prefiltration, the prefilter was equilibrated with sample buffer (20 mM
sodium acetate at either pH 5 with 200 mM NaCl, pH 7.5 without salt, and pH 8.6 with 200 mM
NaCl) at 2 ml/minute for 30 minutes. 90 ml of the mAb was prepared as feed and constituted in
the same buffer as the equilibration buffer. Prefiltration was followed by a buffer chase of 20 ml
buffer (same buffer as the mAb) at 2 ml/minute.40 ml of elution buffer (20 mM sodium acetate
at pH 5 or 8.6 with 1 M NaCl for IEX-S and IEX-Q; 20 mM sodium acetate buffer, pH 7.5 no
salt for HIC) was used to elute the foulant species at 2 ml/minute from the prefilter.The FPLC
showed adsorptive and desorptive events in real-time. The fractions were then analyzed.
The prefiltration membrane was installed on an FPLC (GE Pharmacia, Boston, MA). HIC
prefiltration was performed at pH 5 with salt, pH 7.5 with salt, and pH 8.6 with salt. Buffer A
had the same composition as the mAb buffer with 200 mM NaCl. A lower ionic strength buffer
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of the same pH as the mAb with 0 mM NaCl was used as buffer B (elution buffer) during HIC
prefiltration. Sartobind S and Sartobind Q prefiltration required 200 mM NaCl in buffer A at pH
5 and pH 8.6 but 0 mM NaCl in buffer A at pH 7.5. Buffer B had high ionic strength (1 M NaCl)
during IEX (Sartobind S and Sartobind Q) chromatography.
A 0.2-µm polyethersulfone (PES) bottle top filter was used to remove large aggregates
before prefiltration and virus filtration (normalizing mAb feed aggregate levels). Prefiltration
was performed in flowthrough mode across all prefilters, and the mAb was collected as
flowthrough fractions. A buffer wash step was performed after flowthrough, and an elution strep
was also performed. All fractions were collected for characterization. The flowthrough fraction
was immediately available for virus filtration.
Visual leak integrity tests were performed on the BioEX virus filters at 14.5 psi for 20
seconds before flushing air out from the system. Reservoir pressure was controlled by an
Ashcroft pressure gauge (Part number: EW‐68334‐15; 0-100 psi, resolution 0.1, accuracy ± 0.5
full‐scale). Deionized water filtered with a 0.2-μm bottle top filter was added to the Planova™
Pressure Reservoir (Asahi Kasei, Japan). The BioEX filter was then flushed with 40 L/m2 of DI
water and 40 L/m2 of equilibration buffer. We performed virus filtration in constant-pressure,
dead-end filtration mode. The flowthrough fractions during prefiltration were used as the BioEX
feed. The cumulative mass of the BioEX filtrate was acquired in real-time using a BalanceLink
software connected to a Mettler Toledo scale (Columbus, OH).
A no prefiltration baseline involved removing large aggregates using a 0.2-μm bottle top
filter before BioEX virus filtration. Virus filtration without prefiltration was performed using
mAb B feed at the above-stated buffer conditions without HIC or IEX prefiltration.
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Figure 3.3 below shows the workflow for virus filtration without prefiltration. The
permeate from BioEX filter 1 was introduced as feed to BioEX filter 2.

Figure 3.3: Workflow for BioEX Filtration in Series for mAb B without Prefiltration
Virus filtration with the BioEX virus filter was also performed downstream of size
exclusion-based prefilters (Planova 75N, 0.1-μm, and 0.2-μm PES bottle top filters). The BioEX
virus filter was subsequently flushed with 40 L/m2 of buffer chase and pH 4 elution buffers. All
fractions were collected and subsequently characterized. Figure 3.4 below shows the various
specifications of prefilters used for the study.
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Figure 3.4: Specification of Prefilters and Buffer Conditions used for mAb B Study
The Planova 75N is used in the plasma fractionation industry. Here we investigated its
effectiveness as a size-exclusion prefilter which would remove larger species that could foul the
virus filter. It has a nominal pore size of 75 nm. Planova 75N prefiltration was not performed on
an FPLC. The Planova 75N was connected to a Planova pressure vessel containing the mAb at 5
g/L. The operating pressure of 14 psi was supplied from a pressurized nitrogen bottle. The
permeate was collected on a weighing balance and recorded for flux calculations. The other size-
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exclusion prefilters were bottle top filters (0.1-micron and 0.2-micron). These are sterilizing
grade filters that are typically used to filter all buffer streams prior to introduction to the
manufacturing process. Bottle top filters are manually handled with a low vacuum used to pull
the permeate from the feed along the walls of the receiving bottle to prevent aggregation.
Sartobind membrane adsorbers were adopted as adsorptive prefilters. These include the
sartobind phenyl (HIC prefilter) and the ion exchange prefilters (Sartobind S and Sartobind Q).
The ion exchange prefilters were implemented in flowthrough mode by adding 200 mM NaCl to
the buffer when the absolute value |pH – pI| > 0.5 to maintain high mAb transmission (>0.95).
Multimodal prefilters were not used for this study.
3.2.3

Hydrophobic Interaction Chromatography Based Prefiltration
Hydrophobic interaction chromatography (HIC) prefiltration was used to purify

monoclonal antibodies by leveraging the difference in hydrophobicity between native
conformation mAbs and denatured mAbs or aggregates. A Sartobind phenyl membrane adsorber
(HIC ‘prefilter’) was selected. The membrane matrix is made of stabilized, reinforced cellulose
and is functionalized with phenyl ligands. This prefilter has a bed volume of 3 ml and a nominal
pore size greater than 3µm. The average pore size is 3 - 5µm. HIC prefilters are single
mechanism prefilters. The HIC prefilter is mounted on an FPLC in a flowthrough configuration
to observe the molecular interactions in real-time using the in-built spectrophotometer.
The prefilter was equilibrated at 2 ml/minute with the requisite buffer condition at pH 5,
7.5 or 8.6 for 30 minutes before prefiltration of mAb B feed (90 ml at 5.4 g/L). Prefiltration was
always performed at 2 ml/minute including the equilibration and wash fractions. Buffer chase
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(20 ml) was used to wash off loosely bound mAb from the prefilter over ten minutes followed by
40 ml of elution buffer (same buffer as equilibration buffer without salt) at pH 5, 7.5 or 8.6.
Prefilter flowthrough fractions were collected for virus filtration. The HIC elution
fraction (eluate) was also collected for further analysis. Figure 3.5 below shows the schematic of
a sartobind phenyl prefilter.

Figure 3.5: Cross-sectional Area of a Sartobind Phenyl (HIC) Membrane Adsorber
The prefilter membrane is tightly bound inside the housing. The fluid enters the prefilter
capsule and flows around the membrane housing under the feed pressure, which forces the fluid
to pass through the membrane into the interior flow path (inner core) of the prefilter. This
flowthrough fraction is the prefiltered product of the membrane.
3.2.4 Cation Exchange Chromatography-Based Prefiltration
The prefilter was equilibrated at 2 ml/minute with the requisite buffer condition at pH 5,
7.5, or 8.6 for 30 minutes before prefiltration of mAb B feed (90 ml at 5.4 g/L). Prefiltration was
performed at 2 ml/minute, including the equilibration and wash fractions. Buffer chase (20 ml)
was used to wash off loosely bound mAb from the prefilter over ten minutes, followed by 40 ml
of elution buffer over 20 minutes (same buffer as equilibration buffer with 1 M NaCl) at pH 5,
7.5, or 8.6.
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Strong cation exchange membranes or resins are materials with the attribute of displaying
permanent negatively charged ligands on the surface, which can then be used to partition cationic
species from a sample. Negatively charged exchangers bind positively charged ions (cations).
Cation exchange materials are classified as strong or weak, depending on whether cation
exchange properties change with buffer pH [21].
Partitioning of mAbs occurs by selective adsorption based on the mAb surface charges at
prevailing pH and salt concentration. The cation exchange chromatography (CEX) membrane
adsorber (IEX-S ‘prefilter’) we selected is the Sartobind S membrane adsorber (IEX-S), which
has sulfonic acid ligands (SO3-) and a permanent negatively charged surface. The membrane
matrix is made of stabilized, reinforced cellulose and is functionalized with sulfonic acid, as
shown in Figure 3.6 below.

Figure 3.6: Sartobind-S Matrix-Ligand Structure
IEX-S membrane adsorbers have an affinity for positively charged biomolecules due to
the ligand chemistry. The prefilter used for this work had a membrane volume of 3 ml and a
nominal pore size greater than 3µm. The average pore size is 3 - 5µm. This prefilter was
mounted in an FPLC to perform prefiltration in the flowthrough mode. When the process feed
stream is introduced into the cation exchange prefilter, foulants with cationic characteristics bind
to the oppositely charged functional groups on the IEX-S ligand through Coulombic attraction.
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Following Coulomb's law, the attractive forces between cationic species in the feed stream and
oppositely charged functional groups on the cation exchange ligand is due to electrostatic forces.
3.2.5 Anion Exchange Chromatography-Based Prefiltration
The prefilter was equilibrated at 2 ml/minute with the requisite buffer condition at pH 5,
7.5, or 8.6 for 30 minutes before prefiltration of mAb B feed (90 ml at 5.4 g/L). Prefiltration was
performed at 2 ml/minute, including the equilibration and wash fractions. Buffer chase (20 ml)
was used to wash off loosely bound mAb from the prefilter over ten minutes, followed by 40 ml
of elution buffer over 20 minutes (same buffer as equilibration buffer with 1 M NaCl) at pH 5,
7.5 or 8.6.
Strong anion exchange prefilters are membranes with the attribute of displaying
permanent positively charged ligands on the surface, which can then be used to partition anionic
species (with a negative charge) from a mobile phase. Positively charged exchangers bind
negatively charged ions (anions) by adsorption.
A typical anion exchange chromatography (AEX) membrane is the Sartobind Q
membrane adsorber (IEX- Q), which has quaternary ammonium ligands and a positively charged
surface. The membrane matrix comprises stabilized, reinforced cellulose whose surfaces are
functionalized with quaternary ammonium by hydrogel grafting. The Sartobind-Q matrix-ligand
structure is shown in Figure 3.7 below.

Figure 3.7: Sartobind-Q Matrix-Ligand Structure
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Sartobind-Q prefilter used in this work had a membrane volume of 3 ml and a nominal
pore size greater than 3µm. The average pore size is 3 - 5µm. Table 3.1 below shows the
chemistry of some anion exchange ligands.
Table 3.1: Structure and Potency of some Anion Exchange Ligands
Anion exchangers

Potency

Functional group

Quaternary ammonium (Q)

strong

-CH2-N+-(CH3)3

Diethylaminoethyl (DEAE)

weak

-CH2-CH2-N+-(CH2-CH3)2

Diethylaminopropyl (ANX)

weak

-CH2-CHOH-CH2-N+-(CH2-CH3)2

The strength of anion exchanger ligands represents the charge state and anion
exchangeability of the functional groups within the ligand at different solution pH values. The
strength and weakness of anion exchangers do not refer to these exchangers' binding affinity but
rather the propensity to exchange anions at different pH conditions. The chemical structure of
some weak and strong anion exchange ligands is shown in Figure 3.8 below.

Figure 3.8: Typical Ligands used to Functionalize Anion Exchange Membranes
Diethylaminoethyl and diethylaminopropyl ligands have hydrogen atoms in their
backbone and are prone to deprotonation. Quaternary ammonium has no hydrogen atom in the
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backbone and is not susceptible to deprotonation. Strong anion exchangers show little to no
variation in ion exchange capacity with a pH change, unlike weak anion exchangers.
3.2.6 Capillary Electrophoresis (CE) Characterization
A pharmaceutical analysis system (PA800 plus) by SCIEX (Redwood City, CA) was
used to characterize the various filtration fractions using various modes. The capillary
electrophoresis instrument (PA 800 plus) is a preferred choice for pharmaceutical
characterization of mAb filtration fractions to identify MW variants, charge variants,
glycovariants, and impurities. The mAb fractions to be characterized must be desalted and
normalized to uniform concentrations before sample preparation using the SCIEX protocols. Up
to 72 samples can be loaded at once. Characterization takes place sequentially based on the
programmed software instructions.
The instrument parameters included a 50 μm capillary ID and a 30 cm capillary length.
The distance from the capillary inlet to the transparent detection window was 20cm. Bare fused
silica capillaries were used for CE-SDS or IgG purity/heterogeneity assay. The advantages of CE
include nanoliter injection volumes and exceptional peak resolution using over 1000000
theoretical plates.
Sample preparation for CE-SDS of mAb B involves desalting the filtration fractions with
a 10 kDa MWCO centrifugal filter and reconstituting with DI water to 2 g/L. 10μl of desalted
mAb B filtration fractions was added to 90 μl of proprietary SCIEX gel buffer and loaded onto
the instrument. SCIEX CE-SDS equipment operation protocol was followed for data acquisition
and interpretation. During CE-SDS or IgG purity analysis, 15kV was applied across the capillary
to separate the biomolecules by size only. The induced electric field caused sample components
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to migrate differentially from the inlet to the capillary outlet. A photodiode array detector was
used to measure absorbance yielding an electropherogram in real-time.
The PA800 plus was also used to perform capillary zone electrophoresis (charge variant
analysis) of the mAb fractions. In the charge variant analysis mode, the bare fused silica
capillary was used. All fractions were desalted and reconstituted in DI water. The samples were
loaded in 200 μl vials at 2 g/L into the instrument. SCIEX CZE running protocol was followed to
obtain the electropherogram. The sample components migrate across the capillary by
electroosmotic flow from the inlet to the outlet. Based on the relative migration rates, distinct
peaks are obtained for the various IgG charge variants in the sample. The UV detector was
installed during CZE characterization, and a voltage of 30kV was applied across the capillary.
The UV detector was also used during capillary isoelectric focusing (cIEF)
characterization of mAb fractions. Whereas CZE shows the various charge variants, cIEF shows
the peak distributions of isoforms and their respective isoelectric points. The pI of a biomolecule
is the pH value at which the molecule’s net charge is zero. Capillary isoelectric focusing (cIEF)
is used to determine the pI distribution of components in a sample. During cIEF, the capillary
was filled with proprietary SCIEX ampholytes, which comprise molecules with acidic and basic
moieties that become zwitterionic at their pI. After the sample was injected into the capillary, a
continuous pH gradient was created in the non-flowing ampholyte. Biomolecules migrate bidirectionally to the point in the capillary where their net charge is zero (pI) before the
ampholytes are discharged with the detector determining the retention time of each component
using UV at 280 nm.
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The goodness of fit for the pI markers were determined before using those to determine
sample component pIs. The pI markers used were pI = 4.1, 5.5, 7, 9.5, and 10. Proprietary
synthetic peptides from SCIEX’s cIEF kit were used as the pI markers.
After sample preparation, the PA 800 plus was used to perform a fast-glycan analysis of
the mAb fractions to cleave the glycans. mAb fractions were concentrated or diluted to 1.1 g/L
using centrifugal filters before deglycosylation. 2 μl of recombinant glycosidase (PNGase F from
Promega, Madison, WI) was used to deglycosylate 18 μl of the mAb fractions after the addition
of 1 μl of 1 M DTT to cleave disulfide bonds. A 10 kDa molecular weight cutoff filter (VWR
Life Science, Radnor, PA) was used to separate the released glycans from the deglycosylated
mAbs.
Solid-phase extraction using proprietary SCIEX kit materials was used to purify the
released glycans using immobilized ligands on magnetic beads. Sequential rinses using polar and
non-polar solvents (water and acetonitrile, respectively) ensured that only pure glycans were
captured by the magnetic beads while impurities were decanted off.
A laser-induced fluorescence detector was installed on the PA 800 plus during fastglycan analysis. At the same time, the purified glycans were tagged with a fluorophore (APTS)
during sample preparation. The PA 800 was calibrated with internal standards, and the software
possesses a comprehensive glycan database to characterize glycans. SCIEX supplied all of the
reagents as part of the cIEF, CZE, fast-glycan, and CE-SDS kits, respectively.
3.2.7 Dynamic Light Scattering (Particle Size Analysis)
Particle size analysis by dynamic light scattering (DLS) was used to determine the
particle size distribution of mAb filtration fractions. DLS measures the hydrodynamic radius and,
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by extension, the hydrated diameter of biomolecules in a colloidal solution. DLS can also be
used to obtain the diffusion interaction parameter of analytes in a solution. DLS was performed
using a DelsaNano HC particle size analyzer by Beckman Coulter (Brea, CA). DLS
measurements are susceptible to noise signals from ambient dust interference; therefore, the
cuvettes were rinsed with ultrapure water. The mAb prefiltration and virus filtration fractions
were filtered with a 0.2-micron syringe polyethersulfone filter before DLS measurement.
The instrument was calibrated using 100 nm size standards before starting DLS
measurements. A disposable polystyrene cuvette with one cm pathlength (BrandTech, Essex,
CT) was used for sample collection for measurement. The instrument software was set at 200
acquisitions, and triplicate runs were performed per filtration fraction. Average hydrodynamic
diameter and other diffusion parameters were acquired and recorded for each filtration fraction.
DLS is typically used to quantify the relative intensity of monomers in solution compared
to small oligomers and large aggregates. The 0.2-μm filter was used to ensure the removal of
large aggregates. DLS can determine whether the molecules in solution have a positive diffusion
interaction parameter KD (repulsive intermolecular behavior) or a negative KD where
intermolecular attraction forces dominate [22].
3.2.8 Size Exclusion Analysis
Size exclusion analysis was performed by gel filtration chromatography using a TSKgel
G3000SWXL column (7.8 mm ID x 30 cm, and particle size of 5 μm) made by Tosoh Bioscience
(Grove City, OH). The column was installed on a high-performance liquid chromatography
instrument (Agilent 1260 Infinity Quaternary LC) manufactured by Agilent Technologies (Santa
Clara, CA). The mobile phase was 20 mM sodium phosphate buffer, pH 7.0 with 300 mM
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ammonium sulfate. The column was equilibrated with the mobile phase for one hour before
sample introduction. The mAb fractions were filtered with a 0.2-micron syringe filter and loaded
into 1 ml sample vials. The HPLC was programmed and partitioned the analytes over a twentyminute run.
3.2.9 MALDI Mass Spectrometry
Matrix-Assisted Laser Desorption/Ionization Time-of-flight (MALDI-TOF) mass
spectrometry was used to characterize size and charge variants in the mAb filtration fractions.
This MALDI MS instrument was manufactured by Bruker (Billerica, MA). Virus filtration and
prefiltration fractions of mAb B were desalted and reconstituted in DI water before MALDI MS.
The advantage of using MALDI is rapid and direct ionization of mAbs in solution. mAb samples
were either analyzed in the native state or after reducing the disulfide bonds with dithiothreitol
(DTT).
For DTT-reduced mAb fractions, 20 µL of 10 mM DTT was added to 100 µL of mAb
fraction at 2 g/L. Samples were heated to 95°C for ten minutes and incubated at room
temperature for one hour. A centrifugal filter (10 kDa) was used to desalt the mixture and
remove DTT before reconstituting in DI water for MALDI MS.
Sample preparation for mAb B involved desalting in DI water using a centrifugal filter
and having a 1-2 g/L final concentration. MALDI technique involves pipetting 1-2 µL of each
mAb fraction on a MALDI target plate. 1 µL of dihydroxybenzoic acid is pipetted on top of the
sample to form a crystalline matrix for each fraction. The target plate is then inserted into a mass
spectrometer for laser desorption ionization and time of flight spectrometric studies. With
MALDI, we can observe the biomolecular components' intact masses and the charge of the
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component. The MALDI technique does not decompose the samples and is deemed a soft
ionization technique for obtaining intact sample molecules ions.
MALDI-MS was also used to characterize the glycoform distribution in the various
filtration fractions. After deglycosylation and purification using the SCIEX procedure described
in section 3.26, dihydroxybenzoic acid (DHB matrix) was used to co-crystallize the glycan
samples (analyte) from mAb filtration fractions on the MALDI target plate. MALDI spectra were
obtained for reduced and non-reduced mAb molecules as well as isolated glycans.
3.3 Virus Filtration and Prefiltration Results
3.3.1 BioEX Filtration of mAb B without Prefiltration
The Planova BioEX virus filter was used to filter 5 g/L mAb B without prefiltration at pH
5, pH 7.5, and pH 8.6, respectively, with the earlier described formulation conditions. mAb B
feed was filtered with a 0.2-μm sterile filter, and this was standardized as a no-prefiltration case.
The feed volume of mAb B to the BioEX filter was 90 ml (290 L/m2). The mAb was then filtered
with a BioEX virus filter at a constant pressure of 45 psi. Figure 3.9 below shows the flux decay
associated with mAb B filtration through the BioEX virus filter. The figures on the left plot
throughput on the X-axis while the figures on the right plot time as the X-axis. The flux starts at
a maximum value with ultrapure water filtration. The pre-use buffer flush follows the water
flush. The flux data are stitched together for visual clarity. The flux across the BioEX filter
remains high during buffer flush but rapidly decays at the onset of mAb filtration and recovers to
varying degrees with buffer chase after mAb filtration. Protein recovery and mass balance for no
prefiltration BioEX filtration at pH 5 with salt, pH 7.5 without salt, and pH 8.6 are shown in
Table 3.2 below.
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Table 3.2: Mass Balance/Protein Content for BioEX Filtration of mAb B without Prefiltration in
20 mM Sodium Acetate Buffer, pH 5 with Salt, pH 7.5 without Salt, and pH 8.6 with Salt.
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Figure 3.9: BioEX Filtration of 5 g/L mAb B in 20 mM Sodium Acetate, pH 5 with Salt, pH 7.5
without Salt, and pH 8.6 with Salt.
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Flux decay is more apparent at pH 5 and 8.6 than at pH 7.5. The flux decay is less
decremental at pH 7.5 without salt than at pH 5 with salt. In all three pH conditions, the BioEX
filter loses over 80 percent of the initial flux while delivering a throughput of less than 290 L/m2
that was sterile filtered at the beginning of virus filtration. The mAb is net positively charged at
pH 5 and net negatively charged at pH 8.6. Run 2 BioEX filtration involved the permeate from
pH 5 run 1 BioEX filtration introduced into a second BioEX filter. Run 2 shows reduced fouling
because a portion of the principally fouling species was captured in virus filter run 1. Table 3.3
below summarizes BioEX runs 1 and 2.
Table 3.3: mAb B Filtration Parameters for BioEX Runs 1 and 2 without Prefiltration.
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The application of buffer flush post-mAb filtration results in the flux recovery on the
fouled BioEX filter in all conditions. This points to the reversibility of the virus filter fouling as
blocked pores become unblocked due to the resolubilization and release by desorption of
aggregated biomolecules into filterable molecules. This observation was also reported by
Bieberbach et al. [20]. Concentration polarization of mAbs within the virus filter induces
localized regions of high mAb concentration on the virus filtration membrane leading to the
formation of soluble aggregates that foul the membrane [23]. Soluble aggregates are held by
weak non-covalent bonds that can be disrupted into the monomeric form upon mAb dilution by
the buffer chase [20].
3.3.2 Size Exclusion-Based Prefiltration of mAb B
The 0.2-μm, 0.1-μm, and Planova 75-N were used as prefilters but did not improve
BioEX flux (over 70 percent flux decay) seen in the virus filtration flux data. The bottle-top 0.2μm and 0.1-μm size exclusion-based sterile filters were used as prefilters. Since they are size
exclusion filters, no attempt was made to elute species that may be ‘bound’ to the membrane
surface. The Planova 75N is typically used as a retrovirus filter and was adopted as a ‘prefilter’
for this work. The Planova 75N was operated from a pressure vessel. Since the Planova 75N is a
size exclusion filter, no attempt was made to elute ‘adsorbed’ species from the membrane.
BioEX flux after size-exclusion prefilters will be shown in subsequent sections.
3.3.3 HIC Prefiltration of mAb B
HIC prefiltration of pH 5 mAb B in 20 mM sodium acetate with 200 mM NaCl resulted
in the chromatogram shown in Figure 3.10 below. Results for the two other pH values are in
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Appendix A. A 3 ml Sartobind phenyl membrane adsorber was installed on the FPLC and used
as a HIC prefilter.

Figure 3.10: Chromatogram for HIC Prefiltration of mAb B at pH 5 with 200mM NaCl
Figure 3.10 shows a broad peak representing the mAb flowthrough fraction and a small
elution peak indicating the foulants that were removed by the HIC prefilter. UV absorbance
measurement at a wavelength of 280 nm was used to perform a mass balance of the fractions,
and over 95% mAb recovery was obtained. These fractions were collected and characterized to
obtain molecular-level details about the mAb species in each fraction. The flowthrough fraction
was filtered through a BioEX virus filter.
3.3.4 IEX-S Prefiltration of mAb B
IEX-S prefiltration of pH 5 mAb B in 20 mM sodium acetate with 200 mM NaCl resulted
in the chromatogram shown in Figure 3.11 below. Prefiltration chromatograms for the pH 7.5
without salt condition and pH 8.6 with salt are shown in Appendix A.
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Figure 3.11: Chromatogram for IEX-S Prefiltration of mAb B at pH 5 with 200 mM NaCl
Figure 3.11 shows a broad peak representing the mAb flowthrough fraction and a clearly
defined elution peak representing potential foulants that were removed by the cation exchange
(IEX-S) prefilter. The presence of 200 mM NaCl prevents all the positively charged mAbs at pH
5 from binding to the negatively charged IEX-S prefilter. Mass balance and protein recovery
were performed using UV absorbance measurements at 280 nm, and over 95 percent recovery
was obtained.
3.3.5 IEX-Q Prefiltration of mAb B
The IEX-Q chromatogram of mAb B at pH 5 with salt did not show an elution peak, as
seen in Appendix A. The chromatogram for IEX-Q prefiltration at pH 8.6 with salt showed a
small elution peak (also in Appendix A). IEX-Q prefiltration of mAb B in pH 7.5, 20 mM
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sodium acetate buffer without salt resulted in the chromatogram shown in Figure 3.12 below.

Figure 3.12: Chromatogram for IEX-Q Prefiltration of mAb B at pH 7.5 without Salt
IEX-Q prefiltration of mAb B using a Sartobind Q membrane adsorber effectively
removes fouling species that can cause flux decay in the BioEX virus filter at pH 7.5 without
salt. The absence of salt at pH 7.5 enabled proper capture of foulant species by the positively
charged IEX-Q ligand.
3.3.6 Composite BioEX flux data for mAb B in different buffer conditions with IEX-Q,
IEX-S, HIC, and Size-Based Prefilters
Adsorptive prefiltration of 5 g/L mAb B in the corresponding buffers was performed with
the HIC, IEX-S, and IEX-Q membrane adsorbers in the flowthrough mode at three pH conditions
(5.0, 7.5, and 8.6) described in section 3.2 earlier. BioEX virus filtration was then performed
with the prefilter flowthrough fractions. 90 ml of feed mAb was loaded to the prefilter, and 80 ml
of prefilter flowthrough was loaded to the BioEX filter after prefiltration. Figure 3.13 below
shows the normalized flux values for the BioEX virus filter after prefiltration at pH 5 with the
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various modes of prefilters.

Figure 3.13: mAb B Flux through a BioEX Filter after Prefiltration (pH 5 with 200mM NaCl)
Figure 3.13 shows that size exclusion-based prefilters do not improve BioEX filter flux
and are ineffective in foulant capture. The 0.2-µm, 0.1-µm, and 75N prefilters resulted in over 50
percent BioEX flux decay over 250 L/m2 of feed mAb B (5 g/L in 20 mM sodium acetate buffer,
at corresponding buffer condition). Conversely, the HIC membrane adsorber (prefilter) showed
the best improvement of mAb B flux through the BioEX filter at pH 5 with less than 10 percent
flux decay over 250 L/m2 of feed. Referring to the earlier chromatograms in Figures 3.10 and
3.11, the HIC with a smaller elution peak area performed better than the IEX-S prefilter with
double the HIC's elution peak area. The HIC membrane adsorber shows improved foulant
removal (mAb charge variants and denatured mAbs) than other adsorptive and size-based
prefilters in 20 mM sodium acetate, pH 5 with salt.
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Figure 3.13 shows that the IEX-S prefilter performs well at pH 5 for mAb prefiltration
with less than 20 percent flux decay over a mAb throughput of ~250 L/m2. The adsorptive anion
exchange prefilter (IEX-Q) did not prevent flux decay at pH 5. mAb B is overwhelmingly
positively charged at pH 5 and may not bind the positively-charged IEX-Q ligands. The net
charge (±z) of mAbs changes with buffer pH due to acid-base protonation/deprotonation events
on surface-exposed chemical moieties of the mAb [24-26]. Figure 3.14 below shows the
normalized flux values for the BioEX virus filter after prefiltration at pH 7.5 with the various
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Figure 3.14: mAb B Flux through BioEX Filter after Prefiltration (pH 7.5 no Salt, Except for
HIC where 200 mM NaCl is Required for Hydrophobic Interaction Chromatography)
Figure 3.14 shows that size exclusion-based prefilters do not perform well at pH 7.5. the
ion exchange (IEX-Q and IEX-S) and the hydrophobic interaction chromatography (HIC)
prefilters improve mAb flux through the BioEX filter at pH 7.5. HIC adsorptive prefilters cannot
function effectively without high conductivity buffers. HIC, IEX-S, and IEX-Q membrane
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adsorbers all had steady mAb flux with about ten percent flux decay over 250 L/m2 of mAb. All
three adsorptive prefilters effectively captured principal foulants of the virus filter at pH 7.5.
Figure 3.15 below shows the normalized flux values for the BioEX virus filter after
prefiltration of mAb B in pH 8.6 sodium acetate with salt using adsorptive prefilters and 0.2- µm
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Figure 3.15: mAb B Flux through the BioEX Filter after Prefiltration with Different Prefilters
(pH 8.6 Buffer with 200 mM NaCl)
All adsorptive prefilters typically capture mAb aggregates. The HIC prefilter
preferentially adsorbs denatured monomeric variants, oligomers with increased hydrophobicity,
and post-translationally modified mAb variants.
Figure 3.16 below shows mAb B flux through the BioEX filter sorted according to
prefilter type at different buffer conditions.
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Figure 3.16: Composite Figure for mAb B Flux at pH 5 with Salt, pH 7.5 without Salt, and pH
8.6 with Salt through the BioEX Filter According to Prefilter Mechanisms (A) HIC. (B) IEX-S.
(C) IEX-Q. (D) No Prefiltration.
Figure 3.16 shows that the presence of salt facilitates HIC prefilter performance. HIC
prefiltration results in BioEX flux above 80 percent at pH 5 with salt, pH 7.5 with salt, and pH
8.6 with salt. IEX-S and IEX-Q prefilters do not perform well at pH 8.6, probably because salt
does not favor electrostatic adsorption of biomolecules, and mAb B is unstable in pH 8.6 buffer
(above pI of mAb B). IEX-Q prefilters do not perform well during prefiltration of mAb B at pH
5 and 8.6 in the presence of salt. Table 3.4 below summarizes the biophysical characteristics of
ion exchange ligands and mAb variants at pH 5, 7.5, and 8.6, respectively.
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Table 3.4: Net Charge of mAb Variants at pH 5, 7.5, and 8.6 and Suggested Membrane
Adsorbers Based on Virus Filtration and Prefiltration Studies

Table 3.4 shows that Sartobind Q performs well at pH 7.5 without salt. Use of Sartobind
Q at pH 7.5 results in the best BioEX flux behavior than other prefilter types. Acidic mAb
variants may be a principal precursor of multimerization, denaturation, and BioEX fouling.
3.4 Dynamic Light Scattering (DLS) of mAb B Fractions in pH 5 Sodium Acetate with Salt
Particle size analysis of mAb B fractions was performed using dynamic light scattering.
The results are shown in Figure F1 (appendix F) and represent the hydrodynamic diameter
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distribution for mAb B HIC prefiltration, IEX-S prefiltration, and BioEX filtration fractions at
pH 5 with salt, where IEX-Q was shown not to be effective.
3.5 Size Exclusion Chromatography Analysis of mAb B BioEX Filtration Fractions
A size exclusion chromatography (SEC) was used to perform a size-based analysis of
BioEX filtration fractions of mAb B in pH 5 acetate buffer (200 mM NaCl) without prefiltration.
pH 4 and pH 9 sodium acetate buffers were used to elute foulants from the fouled BioEX filter.
All these fractions were characterized using SEC. The mobile phase (20 mM sodium phosphate
buffer, pH 7.0 with 300 mM ammonium sulfate) was carefully selected to obtain proper peak
resolution of the monomeric and multimeric forms, as shown in Figure 3.17 below.

Figure 3.17: SEC Spectra of mAb B BioEX Filtration Fractions
Figure 3.17 shows the presence of multimers in the buffer chase fraction, which can be
due to reversible aggregates being washed out of the membrane to restore the virus filter flux.
Dimers were present in significant amounts in the buffer chase, pH 4 eluate fraction, and mAb
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feed fraction without prefiltration. The BioEX filtrate has no dimer content due to the 20 nm
cutoff of the virus filter. mAb monomers have a hydrodynamic diameter of around 11-12 nm.
SEC characterization was also performed for HIC prefiltration and IEX-S prefiltration fractions,
as shown in Appendix E. Overall, very little multimer content was observed in the fractions,
reinforcing the reversibility of aggregated species. Supplementary SEC data is shown in
Appendix E.
3.6 Capillary Electrophoresis Characterization of mAb B Fractions
3.6.1 Capillary Isoelectric Focusing (cIEF) Of mAb B Samples
Biophysical property analysis of mAb B feed involves the determination and
quantification of mAb B variants along the pI spectrum. The pH 7.5 condition was selected
because mAb B is within its pI at pH 7.5 and, most notably, there is no salt present at pH 7.5.
The PA 800 plus instrument does not tolerate 50 mM NaCl or more. Figure 3.18 shows the
isoelectric point distribution ratio of acidic, main, and basic variants of mAb B in the feed
sample as determined using capillary isoelectric focusing (cIEF) on the pharmaceutical analysis
system.
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Figure 3.18: Quantification of Peak Areas for cIEF Electropherogram of mAb B Feed at pH 7.5
without Salt
Microheterogeneity of mAbs due to post-translational modifications often results in
changes in biophysical and biochemical properties such as isoelectric point [27-29], which is
observed in the cIEF spectra of mAb B. Given the pI distribution in Figure 3.18, the central
peaks are typically referred to as main or principal variant peaks with pI ranging from 7.3 - 7.6
[29]. mAb B variants with pI values below 7.3 are called acidic variants. Conversely, mAb B
variants with pI above 7.6 are basic variants.
According to the cIEF spectra peak integrations and quantification, mAb B feed has 51.2
percent acidic variants, 40.9 percent main variants, and 7.9 percent basic variants.
3.6.2 Capillary Electrophoresis CE-SDS Analysis of mAb B Fractions Constituted in DI
water after Desalting using Centrifugal Filters
CE-SDS obtains the monomeric quality profile of a mAb sample in terms of product
purity and size heterogeneity. CE-SDS was used to characterize the molecular components
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present in mAb B fractions and the size variation of component peaks, as shown in Figure 3.19
below.

Figure 3.19: CE-SDS for mAb B Purity Analysis from Capillary Electrophoresis (PA800 Plus)
BioEX feed, permeate, and HIC eluate samples were selected and characterized as shown
on the electropherograms in Figure 3.19. Small peaks of fragmented light chains were observed
at 23.5 kDa. Small but unglycosylated mAb monomers preceded the large peaks for the mAb
monomeric molecules [30]. The HIC eluate peak showed slightly higher peak retention times
than the BioEX feed and permeate, further validating that monomeric mAb variants have
microheterogeneity in size, charge, and hydrophobicity [31, 32]. The HIC prefilter preferentially
captures hydrophobicity-induced mAb variants.
3.6.3 Capillary Zone Electrophoresis (Charge Variant Analysis) of mAb B Fractions
Bind-and-elute chromatography with gradient elution from a cation exchange column
was used to partition charge variants of mAb B. mAb B was initially loaded on a Sartobind S
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membrane adsorber in pH 5 sodium acetate without salt (buffer A), and an elution buffer B (pH
8.6 with salt). Gradient elution from pH 5 to 8.6 was too steep for a suitable peak resolution of
the charge variants, and a working pH closer to buffer B’s pH was selected. The Capto S (5 ml)
impact column, a higher binding capacity cation exchange column, was selected for further
work. Buffer A was optimized at pH 6.5, 20 mM sodium acetate without salt, while buffer B was
20 mM sodium acetate buffer, pH 8.6 with 200 mM NaCl. Gradient elution was optimized for
better peak resolution and collection of elution fractions with charge variant partitioning.
Loading of 900 ml of 0.5 g/L mAb B in 20 mM sodium acetate buffer, pH 6.5 without
salt, was performed on the FPLC at 1 ml/min. Fractions were eluted by gradient elution (from 0
percent buffer B to 100 percent buffer B in 100 minutes). The bind-and-elute chromatograms are
shown in Appendix C. The elution fractions were prepared for charge variant analysis using the
pharmaceutical analysis system. The electropherograms for each fraction were integrated
according to acidic peak groups, main and basic peak groups, then quantified as shown in Table
3.5 below.
Table 3.5: Capillary Zone Electrophoresis Peak Analysis for Capto S Fractions of mAb B
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The acidic charge variants were 44.5 percent of the mAb feed and 29.8 percent of eluate
fraction 2. The percentage of acidic variants increased from elution fractions 2 to elution fraction
6 and indicating that some acidic variants have a strong affinity to the cation exchange column.
Buffer pH values below 7.0 would keep the mAbs positively charged and easily captured by
cation exchange columns in bind-and-elute mode [32]. Sartobind S performed well as a prefilter
for mAb B in pH 5 sodium acetate with salt. Low ionic strength buffers are also favored to
prevent the competitive binding of buffer ions to the negatively charged cation exchange ligands.
The percentages of main (dominant) mAb variants decreased from eluate fraction 2 to eluate
fraction 6, which is the inverse trend of the acidic variants. Pooled eluate fractions had variant
percentages, which closely tracked mAb variant percentages in the feed.
3.6.4 Glycan Analysis of mAb B Fractions
Filtration fractions were deglycosylated to characterize the glycan profile and distribution
of glycoforms per filtration pool. BioEX filtration fractions of mAb B (pH 7.5 acetate buffer
without salt) and without prefiltration were prepared for deglycosylation. The fractions were
treated with sodium dodecyl sulfate, dithiothreitol (to reduce the disulfide bonds), and Triton X100 before glycan cleavage by N-glycosidase F (PNGase F). A 10 kDa centrifugal filter was
used to remove mAb fragments, while solid-phase extraction was used to purify the glycans
removed from each mAb fraction for analysis using either MALDI-MS or capillary
electrophoresis. Table 3.6 below shows the glycan structures.
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Table 3.6: Characteristics of Glycans Identified in mAb B Fractions

The various glycans have differences in molecular mass, and depending on mAb
glycoform, these introduce slight differences in molecular mass (size variants). Each mAb
typically has only one glycan appended to each heavy chain on asparagine-297 (N-297). Glycan
occupancy can thus be a determinant of mAb properties primarily in the case where a mAb may
have no glycan appended or mono-glycosylated instead of two glycans per mAb. Figure 3.20
shows the glycan profile of mAb B fractions restricted to the two dominant glycoforms
comprising over 90 percent of the glycans present.
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Figure 3.20: Glycan Analysis for Quantification of G0F and G1F Glycoforms per Filtration
Fraction of mAb B (pH 7.5, 20 mM Sodium Acetate Buffer, without Salt)
The dominant glycoform (G0F) with a molecular weight of 1463 Da was highly
represented in the BioEX filtrate, while the G1F glycoform with a molecular weight of 1625 Da
was highly represented in the HIC eluate. The HIC eluate components are known to comprise the
principal foulants of the virus filter, and it can be deduced that the G1F ratio is directly
proportional to the fouling propensity of a mAb pool. G1F increases by 12 percent from the
BioEX filtrate to the BioEX eluate and increases 12 percent from the HIC prefilter permeate to
the HIC eluate. Conversely, G0F abundance is deduced to correlate with good behavior and
filterability of a mAb pool across a virus filter. Future studies are required to evaluate the
aggregation propensity of mAb monomers according to the glycovariant profile of each pool.
3.7 MALDI MS Analysis of mAb B Fractions
MALDI MS was performed on the various filtration fractions to evaluate the size
heterogeneity of the mAb monomers in the filtration fractions, as shown in Figure 3.21 below.
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The mAb fractions were intact monomers because they were not reduced using (DTT). The
eluate fractions were concentrated (x40) using a 10,000 Da MWCO centrifugal filter.

Figure 3.21: MALDI MS Spectra of mAb B BioEX Fractions without Prefiltration
The molecular weight of intact mAb B monomer in elution fractions pH 4 and 9 is
significantly higher than the monomeric mAb B molecular weight in the BioEX feed and filtrate
fractions. The monomeric peak for mAb B feed (150,968 Da) is centered ~600 Da higher than
the BioEX filtrate. The buffer chase monomeric peak (151,485 Da) is centered ~1200 Da higher
than the BioEX filtrate. The peak for pH 4 eluate is 5000 Da higher than the central peak
position for the buffer chase. The pH 9 eluate peak is centered at ~153,907 Da, significantly
higher than the feed and filtrate peaks, though with much lower intensity.
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Double ionized forms of the mAb were observed within the 77,000 Da – 80,000 Da
range. The principal fouling variants were enriched in the buffer chase and eluate fractions. They
have higher molecular weights than the main isoform of mAb B in the feed. Figure 3.22 below
shows a zoomed-in overlay plot for the monomeric variant peak per BioEX fraction.

Figure 3.22: Zoomed-in MALDI Spectra for Monomeric mAb B Peaks in BioEX Fractions
Figure 3.22 shows the relative peak intensities of fractions and peak width overlap at the
higher molecular weight region (150,000 – 165,000 Da). This overlap around 165,000 Da shows
that the higher molecular weight fractions are marginally enriched in the pH 4 and pH 9 buffer
elution fractions and not artifacts of the buffer condition. MALDI mass spectrometry was
performed for cation exchange (IEX-S) prefiltration fractions after desalting with a spin column,
as shown in Figure 3.23 below. The zoomed-in inset occurs in the 150,000 Da region.
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Figure 3.23: MALDI-MS Spectra for mAb B IEX-S Prefiltration Fractions (Inset at 150 kDa)
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Consistent with the observations for the BioEX filtration fractions, the higher molecular
weight monomeric variants are enriched in the IEX-S eluate fraction. The eluate peak is centered
at 150.3 kDa, while the IEX-S permeate is centered at 149.7 kDa. The peak at 161.5 kDa is
postulated to be a heavily glycosylated mAb B variant and is not visible in the eluate fraction
because of the low eluate concentration. The peak at 173.2 kDa is postulated to be mAb B
monomers (150 kDa) bound to isolated fragments of light chain (23.5 kDa).
MALDI MS analysis was performed for the HIC prefiltration fractions (feed, filtrate, and
eluate) and mAb B feed (titrated to pH 4, 5, and 9) to understand whether pH variation
introduces artifacts into MALDI spectra. The spectra are shown in Figure 3.24 below.

Figure 3.24: MALDI MS of HIC Prefiltration Fractions and mAb B Feed at Different pH
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Figure 3.24 shows that between pH 4 and pH 9, mAb B monomer peaks are centered at
149,400 Da +/- 100 Da, and therefore, titration of mAb B feed to different pH values does not
introduce size artifacts into the MALDI spectrum. This condition was evaluated since pH 4, and
pH 9 eluates were at different pH conditions compared to the feed and permeate (filtrate)
fractions. The HIC feed and filtrate fractions had a similar MW of 149400 Da +/- 100 Da, unlike
the HIC eluate, which was enriched with a higher MW variant at 150,384 Da. The HIC eluate
was at a much lower concentration than the feed and had to be concentrated (x40) using a
centrifugal PES filter (10 kDa MWCO).
We also performed MALDI MS for mAb fractions after dithiothreitol reduction of the
disulfide linkages joining the heavy and light chains of mAb B, as seen in Figure 3.25 below.

Figure 3.25: MALDI MS Spectra of DTT-reduced mAb B BioEX Filtration Fractions
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Figure 3.25 shows the enrichment of a 67000 Da mAb fragment in the elution fractions at
pH 4 and pH 9. This 67,000 Da peak is marginally present in the buffer chase fraction and not
noticeable in the BioEX feed and filtrate fractions. It is hypothesized that this fragment is from a
monomeric mAb variant after DTT reduction. Denatured variants have higher hydrophobicity
and induce multimerization with subsequent fouling of virus filters.
3.8 Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) analysis
Gel electrophoresis was used to analyze the monomeric size variation of mAb B filtration
fractions. SDS PAGE is an electrochemical technique that ensures all the biomolecules present
have the same mass/charge ratio and migrate in the same direction at different rates. The
negatively charged sulfate groups on SDS impart a net negative charge to all analytes in the gel
such that mAb migration from cathode to anode down the gel is based on molecular weight only.
Figure 3.26 below shows the electrophoretogram for BioEX filtration fractions without
prefiltration.

Figure 3.26: SDS PAGE of mAb B BioEX Filtration Fractions without Prefiltration
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We performed SDS PAGE with non-reducing gel buffers, 8 percent polyacrylamide gel
for the separating gel, and 4% for the stacking gel with a voltage of 100V. The non-reducing gel
ensures that the mAb monomers do not break down into heavy (50 kDa) and light (25 kDa)
chains. Consistent with the MALDI MS results, the elution fractions have a higher percentage of
higher molecular weight mAb variants. The higher MW variants weighed between 151.5 kDa
and 156 kDa. The main variant weighed between 149 and 150 kDa. Eight percent separating gel
was discovered to be insufficiently porous for mAb B, and the gel porosity was increased by
reducing the polyacrylamide percentage from 8 percent to 6 percent. In Figure 3.27 below, mAb
B feed was incubated in different buffer pH and salt conditions before SDS PAGE to observe
any attribute changes.

Figure 3.27: SDS PAGE of mAb B Feed Titrated to Different pH Values
Figure 3.27 shows that the presence or absence of salt at pH 4 did not significantly alter
the mAb monomer bands. Between pH 5 and pH 9, there was no significant difference between
the bands. SDS PAGE is not a sufficiently high-resolution technique for studying
microheterogeneity in therapeutic proteins. Figure 3.28 below shows the SDS PAGE spectra for
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BioEX, HIC, and IEX-S prefiltration fractions using the silver staining protocol for SDS PAGE
gels.

Figure 3.28: SDS PAGE of mAb B BioEX (No Prefiltration), HIC, and IEX-S Filtration
Fractions
The silver staining gel technique obtained high-resolution electrophoretograms at low
analyte loading. HIC eluate clearly showed an enrichment of the higher molecular weight
monomeric band than the HIC filtrate. The IEX-S eluate showed a similar trend but was at a low
concentration. The separating gel (5 percent polyacrylamide) was deduced to be more porous
than desired; hence the mAb bands are slightly below 150 kDa.
2D PAGE partitions biomolecules according to charge and size. The immobilized pH
gradient (IPG) strip partitions mAb variants according to pI. Figure 3.29 below shows a 2dimensional PAGE analysis of the mAb B feed. One dimension shows the molecular mass, while
the other dimension shows the isoelectric point. 2D PAGE is not as accurate as CE-SDS;
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however, 2D PAGE allows validating results obtained using other techniques.

Figure 3.29: 2D PAGE of mAb B Feed in a Non-reducing Buffer Condition
Figure 3.29 shows the monomeric variants of mAb B at spots spread out between pI 7.5
and pI 8.5 (+/- 0.5 pH units). The process was not sufficiently developed; hence, the presence of
mAb streaking and relatively high level of fragmentation into heavy chains and light chains. The
charge variants (acidic, main, and basic) are visible at the intact mAb size marker (150 kDa) and
the size marker of the heavy chain (50 kDa).
3.9 Conclusion
Prefiltration is an effective means of improving the filterability of mAbs through a virus
filter when the right prefilter type is selected to remove the fouling species. The importance of
cheaper membrane-based prefilters cannot be overemphasized due to virus filter costs and the
single-use nature of virus filters. With new biologic modalities coming onstream and the pressure
of biosimilar competition, a clearly defined model for prefilter selection is crucial. The
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biopharmaceutical industry has previously relied on empirical means to determine adequate
prefilters for the novel mAbs that come to the market every year.
Size exclusion prefilters did not improve the flux of mAb B, thereby validating the
generally accepted research position that virus filter fouling is attributed to small oligomers less
than 50 nm in size but larger than 20 nm. The smallest size-based prefiltration membrane we
evaluated was 75 nm nominal pore-sized.
HIC membrane adsorbers are a ready option for downstream processing. HIC removes
fouling species in moderate to high ionic strength buffers. Denatured mAb monomers are more
hydrophobic than the native mAb monomers and are therefore captured by HIC prefilters. HIC
membranes function well within several pH units of physiological pH (pH 7) in the presence of
salt, as shown in the pH 5, pH 7.5, and pH 8.6 prefiltration data.
HIC prefilters are not significantly affected by the net charge variability of mAbs in
buffers of different pH. However, as seen in section 4 of this work, HIC prefilter performance
can be affected by some excipients such as arginine that ensure mAb stability in buffer
formulations. Excipients that reduce viscosity or modulate hydrophobic interaction may affect
the effectiveness of HIC prefilters.
Cation exchange prefilters work well when moderate ionic strength buffers are used, and
the mAb’s net charge is opposite the intrinsic charge of the prefiltration membrane. IEX-S
performs well at pH 5 with salt because the salt prevents the binding of all mAb species to the
membrane but permits the oppositely charged variants (potential foulants) to be captured.
Anion exchange membrane adsorbers are the best option for mAb B at pH 7.5 without
salt. At pH 7.5, mAb B is within its pI region (7.1 - 8.0), where the net charge is zero or close to
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zero, and monomeric charge variants that foul the virus filter are captured on the IEX-Q prefilter.
The acidic charge variants of mAb B, especially the sialic acid glycoforms, are hypothesized to
be captured by the positively-charged IEX-Q membrane adsorber.
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4.0 Impact of Buffer Conditions on Filterability of Monoclonal Antibodies
4.1 Introduction
A different, industrially relevant mAb is the subject of this section. Quality by design
philosophy requires a molecular-level understanding of the product quality attributes of mAbs
for effective process design, development, and quality assurance [1]. mAbs are multi-domain
polypeptides with anisotropic tendencies derived from varied surface patches [2, 3]. The
presence of orientation-dependent patches on the exposed regions of a mAb can lead to
anomalous mAb-mAb interactions or mAb-filter interactions [4-8].
When a positively charged patch interacts with a negatively charged patch on an adjacent
mAb molecule, soluble multimerization can occur due to attractive electrostatic interactions [4].
The anisotropic nature of mAbs implies asymmetric charge variations along the surface of a
mAb [8]. mAbs have been shown to have surface patches with asymmetric spectra of
hydrophobicity and hydrophilicity, which can have different fouling tendencies [9].
Over 1300 amino acids come together to form a mAb through secondary, tertiary, and
quaternary structures. These amino acids have different characteristics, including polar versus
non-polar, hydrophobic versus hydrophilic, and positively charged versus negatively charged. As
a result, the biophysical characteristics of the surface-exposed residues change when the buffer
properties are different [10]. In mAb studies, biophysical characteristics are considered
holistically as net characteristics or discrete-wise at the domain or surface-patch level.
As a result of property change in different aqueous environments, mAbs must be
carefully screened for buffer conditions with the best stability and least multimerization
propensity [11, 12]. Mass spectrometry with multi-attribute monitoring (MAM-MS) is becoming
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a technique of choice for characterizing mAb molecular attributes all at once [1, 13-15]. pH and
ionic strength turbidimetric titrations have been used to study mAb multimerization propensity in
aqueous buffers. High throughput screening has also become a technique of choice for research
organizations.
Turbidimetric measurements can determine the role of excipients on mAb stability using
a UV spectrophotometer at 340 nm. Generally, spectrophotometers give turbidity generalizations
on the macro level without discretizing the product's molecular characteristics. Pharmaceutical
analysis systems such as the PA 800 plus have become a technique of choice for product quality
and attribute analysis.
Anomalous behavior of mAbs becomes prevalent at low ionic strengths hence the
usefulness of cation exchange prefiltration and anion exchange prefiltration at specific pH
values. Figure 4.1 below shows the charge and hydrophobicity anisotropy of a mAb.

Figure 4.1: Charge and Hydrophobicity Asymmetry of IgG2a mAb. (RBSB Protein Databank).
Positively Charged Residues in Blue, Negatively Charged Residues in Red, and Hydrophobic
Residues in Yellow.
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Figure 4.1 shows the charge asymmetry of a mAb at a defined pH value which changes
when buffer pH changes [16, 17] because the residues or patches protonate at lower pH values
than the mAb’s pI and deprotonate at higher pH values. The hydrophobic patches, shown in
yellow, interact with other hydrophobic patches on adjacent mAbs or adsorptive membranes
when the salt concentration is sufficient. Arginine is an amino acid that is frequently used as a
buffer excipient. Arginine, as shown in Table 4.1 below, has a distal guanidine group with a pKa
of 13.8 [18].
Table 4.1: Changing Charge States of Arginine at Different Buffer pH Values.

In the table above, the terminal amine (NH3+) is protonated at physiological pH but
becomes deprotonated beyond pH 12. The carboxyl group is always deprotonated except below
pH 2.1, where it becomes COOH. The arginine example is a microcosm of what happens to most
amino acids that are surface exposed on a mAb in varying buffer conditions. Charge anisotropy
attributes should be carefully considered to minimize multimerization and fouling of virus filters.
4.2 Materials and Methods
4.2.1 Materials
Reagents used were Sodium chloride (molecular biology grade > 98% purity), L-arginine
monohydrochloride (cell-culture grade > 98.5% purity), Sodium phosphate monobasic
monohydrate (ACS reagent, > 98% purity), Sodium phosphate dibasic (reagent plus, >99%
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purity), OmniPur sodium acetate trihydrate (molecular biology grade > 99% purity), Glycine (for
electrophoresis, > 99% purity), Acrylamide for synthesis (79-06-1) and glacial acetic acid (100%
purity) sourced from MilliporeSigma (Billerica, MA).
L(+)-Histidine (>98% purity), tris(hydroxymethyl)aminomethane (biotechnology grade,
99% purity), Ammonium sulfate (proteomics grade, > 99.5% purity), and Sodium dodecyl
sulfate (biotechnology grade, > 99% purity) were sourced from VWR Life Science (Radnor,
PA). Nalgene™ rapid-flow™ sterile single-use bottle top filters (0.2 μm and 0.1 μm) were
purchased from ThermoFisher Scientific (Waltham, MA). Ultrapure water with a resistivity of
18.2 MΩ was used for buffer formulation. Precision protein plus MW standard and Bromophenol
blue indicator, Supelco (115-39-9), were sourced from Bio-Rad laboratories (Hercules, CA).
Dithiothreitol (molecular biology grade, >99% purity) was purchased from Gold Biotechnology
(St. Louis, MO).
Other selected prefilters were Viresolve prefilter (VPF) provided by MilliporeSigma
(Billerica, MA), Sartobind® Phenyl nano 3 mL, Sartobind® Q nano 3 mL, 8 mm bed height, and
Sartobind® S nano 3 mL, 8 mm bed height provided by Sartorius (Göttingen, Germany). The
selected virus filter was Planova BioEX (membrane surface area 0.0003m2) provided by Asahi
Kasei Medical (Tokyo, Japan) and the Viresolve Pro (VPro) provided by MilliporeSigma
(Billerica, MA).
TangenX Sius PDn Cassette (30 kDa MWCO, mPES, 0.1 m2) was sourced from Repligen
(Marlborough, MA). SDS MW analysis kit (PN: 390953), Fast glycan labeling and analysis kit
(PN: B94499), CZE rapid charge variant analysis kit (PN: C44790), and Advanced cIEF starter
kit (PN: A80976) were sourced from SCIEX (Redwood City, CA).
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4.2.2 Monoclonal Antibody Sample Preparation and Buffer Conditions
An industrially relevant mAb M was provided by a biopharmaceutical company. It had
been processed through three chromatographic polishing steps. In the previous section, we
studied mAb B, which was subjected to the industry-standard two polishing steps. The isoelectric
point (pI) of mAb M ranged from 5.95 to 6.55. 10.9 g/L mAb M was initially constituted in a
buffer containing 20 mM histidine and 150 mM arginine, pH 5.11. 100 ml portions of mAb M
were subsequently ultrafiltered and diafiltered into pH 5 buffers of 20 mM sodium acetate, 0 M
NaCl, and 200 mM NaCl. The final volume and concentration were 200 ml and 5 g/L
respectively. Several 50 ml portions of mAb M were retained in the original arginine plus
histidine buffer. 200 ml aliquots of 10.9 g/L mAb M were also buffer exchanged into buffers of
20 mM histidine only, pH 5.11 and pH 6.7. pH 6.7 buffers were titrated with glacial acetic acid
and tris base. Final mAb concentrations after UF/DF were 10 g/L and diluted to 5 g/L with
corresponding buffers when required.
The desired mAb concentrations were 5 g/L and 10 g/L, respectively. mAb stock
concentration was measured by UV spectrophotometric analysis at 280 nm using Genesys10 UV
Scanning System (Waltham, MA) with VWR quartz spectrophotometer cell (path length 1 cm;
West Chester, PA). mAb concentration and turbidity were determined by measuring the
absorbance at 280 and 340 nm, respectively.
Buffer exchange was performed by ultrafiltration and diafiltration (UF/DF) of mAb M
using five diafiltration volumes on a TangenX Sius™ LSn HyStream 30kDa tangential flow
filtration (TFF) Cassette (Marlborough, MA). Buffer pH and conductivity were measured using
Orion Star™ A215 pH/conductivity benchtop multiparameter meter from ThermoFisher
Scientific (Waltham, MA). mAb fractions were immediately used for prefiltration or virus
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filtration following buffer exchange or stored at 4oC for less than one week. Aliquoted mAbs
were stored for extended periods at -80oC.
HIC and IEX-S prefiltration of 10 g/L or 5 g/L mAb M was performed using the
Sartobind phenyl and Sartobind S membrane adsorbers (3 ml membrane volume), respectively.
From mAb B studies in the previous section, it had been established that size-exclusion-based
prefilters were ineffective for preventing virus filter flux decay. The research focus was placed
on adsorptive and multimodal prefilters in this section. Prefiltration of mAb M using the VPF
prefilters and Sartobind membranes was performed in the decoupled prefiltration mode before
virus filtration. Figure 4.2 below shows the workflow for prefiltration and virus filtration.
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Figure 4.2: Decoupled Prefiltration / Virus Filtration Workflow and Filtration Conditions
In the workflow above, 50 ml of mAb M was filtered with a 0.2-micron PES filter before
adsorptive prefiltration using the VPF or Sartobind membranes. Elution buffers were used to
desorb the fouling species from the prefiltration membrane. The FPLC showed adsorptive and
desorptive events in real-time. The fractions were then analyzed. Only VPF prefiltration was
performed without the FPLC. Prefiltration conditions are described below.
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The prefilters were installed on an FPLC (GE Pharmacia, Boston, MA). Prefiltration was
performed in flowthrough mode across all prefiltration membranes, and the mAb was collected
as flowthrough fractions. A buffer wash step was performed after flowthrough, and an elution
step was also performed. All fractions were collected for characterization. The flowthrough
fraction was immediately used for virus filtration.
The prefilters were equilibrated at 2 ml/minute with the requisite buffer condition (earlier
described) for 30 minutes before prefiltration of mAb M feed (50 ml at 10 g/L or 5 g/L).
Prefiltration was performed at 2 ml/minute, including the equilibration and wash fractions.
Buffer chase of the same composition as the feed mAb buffer (20 ml) was used to wash off
loosely bound mAb from the prefilter over ten minutes, followed by 40 ml of elution buffer over
20 minutes (same buffer as equilibration buffer with 1 M NaCl for IEX-S). The Sartobind phenyl
required no salt elution in acetate buffer; however, 20 mM histidine plus 150 mM arginine was
used as elution buffer for HIC when mAb was in 20 mM histidine buffer only.
Viresolve prefilter (VPF) prefiltration was not performed on an FPLC. The Planova 75N
was connected to a Planova pressure vessel containing the mAb at 5 g/L. The operating pressure
was 14 psi, supplied by a pressurized nitrogen bottle. The permeate was collected on a weighing
balance and recorded for flux calculations. For the bottle-top filters (0.2 μm), filtration was
manually handled with a low vacuum pulling the permeate gently along the walls of the
receiving bottle to prevent aggregation.
VPro virus filters were operated at 30 psi and equilibrated with 40 L/m2 of water to
remove all the trapped air before buffer and mAb M filtration. Visual leak integrity tests were
performed on the BioEX virus filters at 14.5 psi for 20 seconds before flushing air out from the
system. Reservoir pressure was controlled by an Ashcroft pressure gauge (Part number: EW‐
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68334‐15; 0-100 psi, resolution 0.1, accuracy ± 0.5 full‐scale). Deionized water filtered with a
0.2 μm bottle top filter was added to the Planova™ Pressure Reservoir (Asahi Kasei, Japan).
The BioEX filter was flushed with 40 L/m2 of DI water and 40 L/m2 of formulation
buffer. We performed virus filtration in constant-pressure (45 psi), dead-end filtration mode. The
flowthrough fractions during prefiltration were used as the BioEX feed. The cumulative mass of
the BioEX, VPro, and VPF permeate was acquired in real-time using a BalanceLink software
connected to a Mettler Toledo scale (Columbus, OH).
A no prefiltration baseline involved removing any large aggregates using a 0.2-μm bottle
top filter before virus filtration. Virus filtration without prefiltration was performed using mAb
M feed at the above-stated buffer conditions.
Figure 4.3 below shows the membrane cross-section of the BioEX hollow-fiber virus
filter showing the void and capillary structure of each hollow fiber from the inside to the outside.

Figure 4.3: Virus Filtration Mechanism of the Planova BioEX [19].
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The BioEX works by size exclusion principle utilizing the 20 nm diameter capillary
pores. The membrane is made of hydrophilized PVDF hollow fibers. Viruses, mAb dimers, and
multimers (> 20 nm) can block the narrow capillary pores. Virus filters are typically designed to
have high sieving coefficients for mAbs hence the asymmetric design of the VPro where the
open support structure faces the feed stream. In Figure 4.3, the BioEX virus filter shows a void
and 20 nm-capillary structure where voids are connected by multiple tortuous capillary paths.
Blockage of a few capillaries leaves room for redirection of the mAb product from that void
through any other open capillary to the subsequent void or until all capillaries are blocked. Virus
filters are designed to maintain high mAb sieving coefficients (>0.95) [20]. Figure 4.4 shows the
transport of two adjacent mAb monomers in the 20 nm capillary region of a BioEX filter.

Figure 4.4: mAb Monomers Passing Through the 20 nm Capillary of the Planova BioEX
Figure 4.4 theoretically illustrates two mAb monomers with surface charge asymmetry
moving through the capillary region of the BioEX membrane. The oppositely charged patches
transiently interact due to electrostatics and slow down the flux of protein through the virus filter
with the possible outcome of blocking the virus filter pore through soluble multimerization.
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4.2.3 Capillary Electrophoresis (CE) Characterization
Capillary electrophoresis was performed using the PA800 plus by SCIEX (Redwood
City, CA). Different characterization modes of the pharmaceutical analysis system were
employed. Detailed descriptions are presented in section 3.2.6. The PA800 plus has a 50 μm
capillary ID and a 30 cm capillary length. The distance from the capillary inlet to the detection
window was 20 cm. Bare fused silica capillaries were used for CE-SDS and IgG
purity/heterogeneity assay. 15kV was applied across the capillary during CE-SDS and IgG purity
analysis to resolve the analytes. A photodiode array detector was used to obtain an
electropherogram in real-time.
Capillary zone electrophoresis (charge variant analysis) of the mAb fractions was also
performed. Bare fused silica capillary was used in the charge variant analysis mode. Sample
components migrate across the capillary by electroosmotic flow from the inlet to the outlet.
Based on the relative migration rates, distinct peaks are obtained for the various IgG charge
variants in the sample. The UV detector was used during CZE characterization, and a voltage of
30 kV was applied across the capillary. The UV detector was also used during capillary
isoelectric focusing (cIEF) characterization of mAb fractions.
4.2.4 Dynamic Light Scattering (Particle Size Analysis)
Dynamic light scattering (DLS) was used to determine the hydrodynamic diameters of
mAb molecules in the various filtration fractions. DLS was performed using a DelsaNano HC
particle size analyzer by Beckman Coulter (Brea, CA). DLS measurements are susceptible to
noise signals from ambient dust interference; therefore, the cuvettes were rinsed with ultrapure
water, and the mAb fractions were filtered with a 0.2-micron syringe polyethersulfone filter.
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The instrument was calibrated using 100 nm size standards before starting DLS
measurements. A disposable polystyrene cuvette with a 1 cm pathlength (BrandTech, Essex, CT)
was used for sample collection for measurement. The instrument software was set at 200
acquisitions, and triplicate runs were performed per filtration fraction. Average hydrodynamic
diameter and other diffusion parameters were acquired and recorded for each filtration fraction.
DLS was used to evaluate the diffusion interaction parameter KD. A positive value
denotes repulsive intermolecular forces, and a negative value denotes attractive intermolecular
forces [21].
4.2.5 Size Exclusion Analysis
Size exclusion analysis was performed using a TSKgel G3000SWXL column (7.8 mm ID
x 30 cm, and particle size of 5 μm) made by Tosoh Bioscience (Grove City, OH). The column
was installed on a high-performance liquid chromatography instrument (Agilent 1260 Infinity
Quaternary LC) manufactured by Agilent Technologies (Santa Clara, CA). The mobile phase
was 20 mM sodium phosphate buffer, pH 7.0 with 300 mM ammonium sulfate. The SEC column
was equilibrated with the mobile phase at 0.9 ml/minute for one hour before sample introduction.
The mAb fractions in requisite buffers were filtered with a 0.2-micron syringe filter and loaded
into 1 ml sample vials. The HPLC was programmed and partitioned the analytes over a twentyminute run at 0.9 ml/minute. 10 μl of samples were injected into the column and analyzed by
HPLC.
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4.2.6 MALDI Mass Spectrometry
Matrix-Assisted Laser Desorption/Ionization Time-of-flight (MALDI-TOF) mass
spectrometry was used to characterize mAb filtration fractions. This MALDI MS instrument was
manufactured by Bruker (Billerica, MA). Due to the unstable nature of mAb M, samples were
retained in their filtration buffer conditions during mass spectrometry. Desalting was not
performed. MALDI-MS involves pipetting 1-2 µL of each mAb fraction on a target plate in
filtration buffer condition and co-crystallizing with sinapic acid. The target plate is then inserted
into the instrument. MALDI MS outputs the analyte's intact mass and the ionization state of the
analyte (singly versus double ionized). MALDI MS does not decompose the samples and is
deemed a soft ionization technique for characterization. Sinapic acid was used as the
immobilization matrix to co-crystallize the mAb fractions (analyte) on the MALDI target plate.
4.3 mAb M Filtration Results
4.3.1 BioEX Virus Filtration of mAb M In Sodium Acetate Buffer without Prefiltration
The Planova BioEX virus filter was used to filter 5 g/L mAb M in 20 mM sodium acetate
buffer with and without salt and no prefiltration at pH 5 with the earlier described formulation
conditions. The mAb was filtered with a 0.2-micron bottle top filter. mAb M was then filtered
with a BioEX virus filter at a constant pressure of 45 psi. Figure 4.5 below shows the flux decay
associated with filtration of mAb M in pH 5 sodium acetate buffer through the BioEX virus filter
without adsorptive prefiltration.
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Figure 4.5: BioEX Filtration of mAb M in pH 5 Sodium Acetate Buffer, with and without Salt.
BioEX filter fouling and flux decay with mAb M is drastic in sodium acetate buffer at pH
5. In the presence and absence of salt, the BioEX filter loses over 80 percent of the initial flux
while delivering throughput under 140 L/m2 of mAb feed. The presence of 200 mM sodium
chloride marginally improved the flux decay by 10 percent over the flux decay without salt. mAb
M has an isoelectric point range between 5.95 and 6.55. The pH 5 condition is outside the net
charge neutrality region of mAb M (pI = 5.95 - 6.55). All mAb M variants would be positively
charged at pH 5, which is 1 pH unit below the isoelectric point region. Further characterization
was performed to understand the molecular level interactions that lead to rapid fouling and is
described further in the results.
Table 4.2 below shows the mass balance of the above BioEX filtration fractions where
greater than 96% mAb M recovery was achieved.
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Table 4.2: Mass Balance of mAb M in pH 5 Sodium Acetate (with and without Salt)

The BioEX filter demonstrated mAb sieving coefficients above 0.96 even though the
mAb rapidly fouled the virus filter. In both experimental instances, the application of buffer flush
post-mAb filtration resulted in the recovery of flux on the fouled BioEX filter up to 60 percent of
initial flux. This phenomenon suggests desorption or reversibility of the fouling species with
buffer dilution where soluble multimers resolubilize upon buffer dilution [22].
Further flux experiments were performed with mAb M permeate from the previous
BioEX filtration (with salt), where the BioEX run 1 permeate was introduced as feed to a new
BioEX filter (designated as run 2 BioEX filter). The flux result is shown in Figure 4.6 below. In
both instances, no prefiltration (except 0.2-micron sterile filtration) was performed before virus
filtration.
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Figure 4.6: Run 1 and 2 BioEX Filtration of 5 g/L mAb M in pH 5, 20 mM Sodium Acetate
Buffer with 200 mM NaCl, 0.2-µm Prefiltration
Run 2 BioEX filtration shows reduced fouling because a significant portion of the
principally fouling species was captured in BioEX filter run 1. Buffer dilution of the mAb
permeates typically occurs during virus filtration. Consequently, the feed concentration changed
from 4.8 g/L for run 1 to 4.4 g/L for run 2, as shown in Table 4.3 below. With a reduced feed
concentration in run 2, a better flux performance is typically expected since mAb filterability
correlates with feed concentration. Concentration polarization of mAbs is postulated to occur
within the capillaries of the BioEX hollow fibers. Concentration polarization is hypothesized to
cause apparent high mAb concentration on the membrane’s boundary layers, leading to the
formation of reversible multimers that foul the membrane [20]. Reversible multimers are joined
by non-covalent bonds, which can be disrupted into the monomeric form upon mAb dilution by
the buffer chase [22]. The mass balance for mAb concentration of run 1 and run 2 fractions is
shown in Table 4.3 below.
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Table 4.3: Mass Balance for BioEX Run 1 and 2 Fractions of mAb M in pH 5 Sodium Acetate

Run 2 feed concentration was slightly lower than run 1 feed concentration because run 1
permeate was reintroduced as run 2 feed. In both instances, high mAb recovery was obtained.
4.3.2 BioEX Filtration of mAb M in Sodium Acetate Buffer with HIC Prefiltration
Hydrophobic interaction chromatography (HIC) prefiltration was used before BioEX
filtration of this batch of mAb M in 20 mM sodium acetate buffer, pH 5, and 200 mM NaCl. The
resulting chromatogram is shown in Figure 4.7 below.
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Figure 4.7: Chromatogram for HIC Prefiltration of mAb M at pH 5 with 200 mM NaCl
Figure 4.7 shows a broad peak representing the mAb flowthrough fraction and no distinct
elution peak for fouling variants removed by the HIC prefilter. The elution buffer was the same
as the loading buffer and could not desorb foulants from the prefilter. The flowthrough fraction
was filtered through a BioEX virus filter, as shown in Figure 4.8 below. It resulted in significant
flux improvement over the no-prefiltration cases.

Figure 4.8: BioEX Filtration of mAb M in pH 5 Sodium Acetate Buffer after HIC Prefiltration
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Figure 4.8 shows that adsorptive prefiltration using a HIC membrane adsorber improved
the flux performance of mAb M in pH 5 sodium acetate buffer. Flux decay over a throughput of
220 L/m2 was about 40 percent. Conversely, over 80 percent flux decay was observed without
prefiltration with a throughput of 140 L/m2.
4.3.3 Virus Filtration of mAb M in 20 mM Histidine Plus 150 mM Arginine Buffer Without
Prefiltration
This mAb was determined to be unstable during process development and was therefore
optimized for storage in 20 mM histidine plus 150 mM arginine at pH 5.11. Virus filtration was
performed in this original buffer condition without prefiltration to study the filterability and
fouling propensity, as shown in Figure 4.9.

Figure 4.9: BioEX Filtration of 5 g/L mAb M in pH 5.11, 20 mM Histidine plus 150 mM
Arginine Buffer without Prefiltration
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The result shows minor flux decay during mAb M filtration in the original buffer
condition with the BioEX virus filter without prefiltration. Arginine is known to reduce
hydrophobicity-induced multimerization of monomeric species, resolubilize multimers and
facilitate refolding of thermally unfolded proteins [23-26]. Figure 4.10 below shows the BioEX
flux data for 10 g/L mAb M in the original histidine plus arginine buffer formulation at pH 5.11.

Figure 4.10: BioEX Filtration of 10 g/L mAb M in pH 5.11, 20 mM Histidine Plus 150 mM
Arginine Buffer without Prefiltration
Figure 4.10 shows that BioEX filtration of mAb M in the original buffer condition at a
mAb concentration of 10 g/L resulted in excellent flux and little fouling. The mass balance of
this experiment is shown in Table 4.4 below.
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Table 4.4: Mass Balance for BioEX Fractions of 10 g/L mAb M in pH 5.11, 20 mM Histidine
Plus 150 mM Arginine Buffer

Figure 4.10 shows that little fouling of the virus filter occurred, while Table 4.4 shows
that 99 percent of the feed was recovered in the permeate without the need for a buffer chase to
resolubilize fouling species.
4.3.4 Virus Filtration of mAb M in 20 mM Histidine (Only) Buffer Without Prefiltration
To study the impact of excipients on the filterability of mAb M, we performed buffer
exchange and virus filtration after removing arginine from the formulation by buffer exchange
using UF/DF. Figure 4.11 below shows the flux of 10 g/L mAb M in 20 mM histidine buffer
(only) through the BioEX virus filter at pH 5.11 and without salt.
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Figure 4.11: BioEX Filtration of 10 g/L mAb M in 20 mM Histidine Buffer (without Salt) at pH
5.11 without Prefiltration
After removing arginine from the mAb formulation at pH 5.11, there was still no
significant fouling of the BioEX virus filter. Figure 4.12 below shows the flux of 5 g/L mAb M
in 20 mM histidine buffer, pH 5.11, through a VPro virus filter with and without Viresolve
prefilter (VPF) multimodal prefiltration.

Figure 4.12: VPro Filtration of 5 g/l mAb M in pH 5.11, 20 mM Histidine Buffer with and
without VPF Prefiltration
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Figure 4.12 showed 30 percent flux decay with the VPro virus filter without prefiltration.
However, the VPF prefilter resulted in significant improvements in mAb M filterability with less
flux decay. It was decided to perform virus filtration of mAb M at pH 6.7, above the pI range for
this mAb. Figure 4.13 below shows the VPro flux of 5 g/L mAb M in pH 6.7, 20 mM histidine
buffer without prefiltration.

Figure 4.13: VPro Filtration of 5 g/L mAb M in 20 mM Histidine Buffer (Only) at pH 6.7
without Prefiltration
At pH 6.7, mAb M showed about 35 percent flux decay on the VPro virus filter without
prefiltration. It is hypothesized that reversal of the monomeric net charge of mAb M occurs from
a net positive charge at pH 5.11 to a net negative charge at pH 6.7 since the pI of this mAb is
between 5.95 and 6.55. Net charge reversal due to pH is theorized to cause monomeric selfassociation at the membrane boundary layer where concentration polarization occurs.
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4.3.5 Virus Filtration of mAb M in pH 6.7, 20 mM Histidine Buffer with Adsorptive
Prefiltration (Sartobind S, Sartobind Phenyl, and Viresolve Prefilter)
Adsorptive prefiltration was performed with the HIC, IEX-S, and VPF prefilters in the
flowthrough mode, followed by virus filtration. Figure 4.14 below shows the chromatogram with
HIC and IEX-S prefilters for mAb M in 20 mM histidine buffer, pH 6.7.
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Figure 4.14: (A) HIC Prefiltration of 10 g/l mAb M in pH 6.7, 20 mM Histidine Buffer. (B)
IEX-S Prefiltration of 10 g/l mAb M in pH 6.7, 20 mM Histidine Buffer.
From the chromatograms in Figure 4.14, the HIC has a smaller elution peak area
compared to the IEX-S prefilter, which is much larger. The HIC prefilter is theorized to
optimally target the removal of hydrophobicity-induced foulant species (possibly denatured
mAbs) than ion-exchange mechanism adsorptive prefilters. Figure 4.15 below shows the flux
behavior of mAb M through the VPro virus filter after HIC and IEX-S prefiltration.
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Figure 4.15: (A) VPro Filtration of 10 g/l mAb M in pH 6.7, 20 mM Histidine Buffer after HIC
Prefiltration. (B) VPro Filtration of 10 g/l mAb M in pH 6.7, 20 mM Histidine Buffer after IEXS Prefiltration.
Both the HIC and cation exchange prefiltration (IEX-S) significantly improves the flux of
mAb M through the VPro virus filter and show less than 10 percent flux decay compared to 30
percent flux decay without prefiltration. All adsorptive prefilters preferentially adsorb denatured
variants, multimers with increased hydrophobicity, and post-translationally modified mAb
variants with charge asymmetry. The size exclusion-based prefilters do not perform well
typically, as shown for the no prefiltration instances where 0.2- µm sterile filters were used.
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4.4 mAb M Characterization
4.4.1 Dynamic Light Scattering (DLS) Characterization of mAb M Fractions
Particle size analysis of mAb M fractions was performed using a DelsaNano DLS. Figure
4.16 below shows the size spectra for mAb M filtration fractions in 20 mM sodium acetate
buffer, pH 5 (with and without salt), DI water, 20 mM histidine buffer, pH 5.11, pH 6.7, and 20mM histidine plus 150 mM arginine, pH 5.11.

A

B
Figure 4.16: (A) DLS of mAb M Fractions in Sodium Acetate Buffer with/without Salt and in
DI Water. (B) DLS of mAb M in 20 mM Histidine pH 5.11, pH 6.7, and 20 mM Histidine Plus
150 mM Arginine Buffer Formulations for Stability Studies.
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DLS data in Figure 4.16A above reinforces results from CE-SDS, showing that desalting
the mAb causes fragmentation. Fragmentation is shown by the black spectrum line with a
hydrodynamic diameter of less than 5 nm. Sodium acetate buffer with and without salt also
shows a low hydrodynamic diameter for mAb M at less than 9 nm. Figure 4.16B shows that
mAb M had the least hydrodynamic diameter in the pH 5.1 histidine buffer, closely followed by
the original buffer (pH 5.1 histidine plus arginine). pH 6.7 histidine buffer was the least stable
for mAb M. Figure 4.17 below shows the particle size distribution of mAb M in the original
buffer (20 mM histidine plus 150 mM arginine).

A

B

Figure 4.17: (A) Differential Intensity for mAb M in Original Buffer. (B) Differential Intensity
for mAb M in pH 5 Sodium Acetate Buffer with Salt after Desalting in DI Water
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Figure 4.17A and 4.17B above shows the stability of mAb M in arginine versus when the
buffer is desalted and reconstituted in DI water, where it fragments and forms irreversible large
aggregates at the same time.
Stability studies for mAb M were designed to obtain further information about the
molecular characteristics of mAb M monomers in different salt conditions at its pI. High salt
concentrations can denature a mAb. We evaluated the effect of high salt concentrations on mAb
M in histidine buffer by titrating to pH 6.3 because pH 6.3 was within the net charge neutrality
region of this mAb. Figure 4.18 below shows DLS data for mAb M in 20 mM histidine buffer
(pH 6.3 and different ionic strengths).

Figure 4.18: Differential Intensity for mAb M in 20 mM Histidine Buffer, pH 6.3 at Different
Ionic Strengths
Figure 4.18 shows a direct correlation between salt content and multimerization of mAb
M, resulting in increased hydrodynamic diameters. As the salt concentration goes up, the
hydrodynamic diameter goes up. Above 1 M NaCl, the mAb monomers multimerize and show
125

increased turbidity. Figure 4.19 below shows the effect of mAb concentration on the
hydrodynamic diameter of mAb m in 20 mM histidine buffer at pH 6.3 and 6.7, respectively.

A

B

Figure 4.19: (A) DLS Size Analysis of mAb M in 20 mM Histidine Buffer, pH 6.3, at Different
Concentrations. (B) DLS Size Analysis of mAb M in 20 mM Histidine Buffer, pH 6.7, at
Different Concentrations.
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The hydrodynamic diameter of mAb M positively correlates with the mAb concentration
at pH 6.3 and 6.7. 22 g/L mAb M had the highest hydrodynamic diameter of 18.4 nm and 19.2
nm at pH 6.3 and 6.7, respectively. 3.3 g/L mAb M in pH 6.3 histidine buffer had the least
hydrodynamic diameter of 11.8 nm. The diffusion interaction parameter, KD, was obtained for
mAb M at the pH conditions of 6.3 and 6.7 in histidine buffer only, as shown in Figure 4.20.

A

B

Figure 4.20: Plot of Diffusion Coefficient Versus Concentration of mAb M in 20 mM Histidine
Buffer at (A) pH 6.3. (B) pH 6.7.
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Figure 4.20 above shows that mAb M has a more negative diffusion interaction parameter
at pH 6.7 than pH 6.3. A more negative diffusion interaction parameter implies a slightly higher
intermolecular attraction force. mAb M, therefore, has a higher multimerization tendency at pH
6.7, which is above its pI range (5.95 - 6.55), than at pH 6.3, which is within its pI range.
4.4.2. Size Exclusion Chromatography Analysis of mAb M Filtration Fractions
HPLC SEC chromatography was used to perform a size-based analysis of mAb M
filtration fractions. The mobile phase was carefully optimized to obtain proper peak resolution of
the monomer and multimeric forms. Figure 4.21 below shows the concentration-dependent
chromatograms of mAb M constituted in 20 mM histidine buffer, pH 6.3.

Figure 4.21: HPLC SEC of mAb M in 20 mM Histidine Buffer, pH 6.3, at Different mAb M
Concentrations
Figure 4.21 shows that dimers are present in small percentages at 13.2 g/L, 17.6 g/L, and
22 g/L. The mAb monomeric peak height is directly proportional to the mAb concentration.
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However, the addition of NaCl up to 3.75 M did not induce dimerization of 2.5 g/L mAb M in
pH 6.3 histidine buffer, as shown in Figure 4.22 below.

Figure 4.22: HPLC SEC of 2.5 g/L mAb M in 20mM Histidine Buffer, pH 6.3, at Different
Buffer Salt Concentrations (1 M NaCl, 1.88 M NaCl, 2.5 M NaCl, and 3.75 M NaCl).
mAb M appears to foul virus filters by monomeric self-association of denatured or PTM
variants at the surface of virus filtration membranes when in histidine buffer leading to
soluble/reversible aggregation. Large irreversible aggregates are not typically found in the
filtration fractions at normal buffer conditions, even with changes in salt content.
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4.4.3 Capillary Electrophoresis Characterization of mAb M Fractions
4.4.3.1 Capillary Isoelectric Focusing (cIEF) of mAb M Sample
Capillary isoelectric focusing data was obtained for mAb M feed to optimize the buffer
parameters used in this study. Figure 4.23 below shows the isoelectric point distribution ratio of
acidic, main, and basic isoforms of mAb M in the feed sample as determined using the PA 800
plus pharmaceutical analysis system.

Figure 4.23: (A) c-IEF of mAb M in pH 5.11, 20 mM Histidine, 150 mM Arginine Buffer.
(B) Isoform Distribution of mAb M in pH 5.11, 20 mM Histidine, 150 mM Arginine Buffer.
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Microheterogeneity of mAbs due to post-translational modifications often results in
surface charge asymmetry, hydrophobicity differences, and isoelectric point differences [27-29].
The cIEF spectra of mAb M show three main isoforms, with 5.4 percent of the basic variant, 71
percent of the main variant, and 23.5 percent of the acidic variant. mAb M variants with pI
values below 6.29 are acidic variants. Conversely, mAb M variants with pI above 6.36 are basic
variants. According to the cIEF spectra peak integrations and quantification, mAb M shows less
than half of the acidic variant ratio of the previously studied mAb B.
4.4.3.2 Capillary Electrophoresis CE-SDS Analysis of mAb M Fractions
CE-SDS was used to evaluate the purity and size homogeneity of mAb M filtration
fractions by capillary electrophoresis on the PA 800 plus. The CE-SDS electropherogram for
mAb M in different buffer conditions is shown in Figures 4.24A, 4.24B, and 4.24C below.
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A
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Figure 4.24: CE-SDS Purity Analysis of mAb M Fractions using PA800 Plus. (A) mAb M in pH
5.11 Histidine plus Arginine Buffer, pH 5.11 and pH 6.7 Histidine Only Buffers, respectively.
(B) CE-SDS of mAb M in 20 mM Histidine Buffer, pH 5.11 for VPF and VPro Fractions (C) CE
SDS of mAb M BioEX Fractions without Prefiltration (pH 5.11, 200mM NaCl)
Figure 4.24A shows that the mAb peaks do not differ significantly between buffer types
with clearly resolved peaks for the monomeric variants and aggregate peaks (monomer plus
fragment). pH 6.7 histidine buffer showed the highest percentage area for the higher MW
monomeric and higher MW aggregate peaks. Figure 4.24B, where mAb M is in histidine buffer
(only), shows the higher molecular weight peaks that consist of one monomer plus an isolated
mAb fragment. This higher molecular weight peak was obtained between 171 and 175 kDa.
Monomeric mAb variants have been reported to possess microheterogeneity in size, charge, and
hydrophobicity [30, 31]. Figure 4.24C shows no monomeric forms of mAb M and suggests mAb
instability after desalting, leading to some fragmentation and some irreversible aggregation, as
confirmed with DLS.
CE-SDS was performed for the HIC and IEX-S prefiltration fractions to evaluate size
variants in the various fractions; feed, permeate, and eluate, as shown in Figure 4.25 below.
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Figure 4.25: (A) CE SDS Electropherogram of mAb M HIC and VPro Fractions in pH 6.7,
20mM Histidine Buffer (B) CE SDS Electropherogram of mAb M IEX-S and VPro Fractions in
pH 6.7, 20 mM Histidine buffer

134

Three main monomeric variants were observed from the CE-SDS electropherogram of
mAb M HIC, IEX-S, and VPro fractions, as shown in Figure 4.25. In the feed fractions of both
the HIC and IEX-S prefilters, peak C is most abundant. Peak C is the monomeric variant with the
highest MW. In the permeate fractions of the HIC and IEX-S, peak C decreases, and peak B
becomes most abundant. Peak C decreases even further in the VPro permeate of both Figures
4.25A and 4.25B. The variant with slightly higher molecular weight is theorized to be a
glycoform with heavier glycans attached than variant B, and variant A. Eluate concentration was
too low for detection. The peak at 173.2 kDa is likely an aggregate comprising a monomer (150
kDa) bound to an isolated fragment (23.5 kDa), as reported by Cao et al. [32].
4.4.4 Sodium Dodecyl Sulfate (SDS) Polyacrylamide Gel Electrophoresis (PAGE) Analysis
Gel electrophoresis was used to analyze the monomeric size variation of mAb M
filtration fractions. The negatively charged sulfate groups impart net negative charges to all
analytes in the gel such that mAb migration from cathode to anode down the gel is based on
molecular weight only. Figure 4.26 below shows the SDS PAGE electrophoretogram for mAb M
formulations during gradual desalting to evaluate stability.
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Figure 4.26: SDS PAGE of mAb M Samples in Original Buffer and when in DI Water
SDS PAGE was performed with non-reducing gel buffers, 8 percent polyacrylamide gel
for the separating gel, and 4% for the stacking gel with a voltage of 100V. The non-reducing gel
ensures that the mAb monomers do not break down into heavy (50 kDa) and light (25 kDa)
chains. The mAb became unstable during the diafiltration process as the formulation buffer was
replaced with DI water. The mAb showed precise bands clustered around 150 kDa in lane 1. In
lane 2, some streaking of the monomeric bands occurs after buffer exchange with three
diavolumes of water. A dimer band also formed in lane 2. Lanes 3 and 4 lack the monomeric
bands at 150 kDa when the mAb is completely desalted by buffer exchange with 10 diavolumes
of DI water. It is theorized that a significant portion of the mAb formed large irreversible
aggregates in DI water.
In Figure 4.27 below, mAb M BioEX filtration fractions were characterized using SDS
PAGE to observe any attribute changes between fractions.
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Figure 4.27: SDS PAGE of mAb M Feed Titrated to Different pH Values
Figure 4.27 shows that size variants could not be resolved between the BioEX feed and
the BioEX filtrate using SDS PAGE. The buffer chase appeared to have lower molecular weight
bands than the feed and permeate. The type of ultrafiltration/diafiltration protocol did not
significantly alter the mAb monomer bands. SDS PAGE is not a sufficiently high-resolution
technique for studying microheterogeneity in therapeutic proteins. Figure 4.28 below shows the
SDS PAGE spectra for BioEX filtration fractions of mAb M in 20 mM sodium acetate buffer
without salt.
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Figure 4.28: SDS PAGE of BioEX Fractions (No Prefiltration) for mAb M in 20 mM Sodium
Acetate Buffer, No Salt
mAb M is highly unstable in low pH and low ionic strength buffers, as shown in Figure
4.28 above; the monomeric peaks were not present in this condition. It is theorized that the mAb
monomers multimerize into large, irreversible aggregates. At the same time, a portion
disintegrates into small, 25 kDa fragments. This phenomenon was supported by capillary
electrophoresis and MALDI analysis.
4.4.5. MALDI MS Characterization of mAb M Fractions
MALDI MS was performed on the various filtration fraction to evaluate the size
heterogeneity of mAb monomers in the VPro feed and permeate filtration fractions, as shown in
Figure 4.29 below.
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Figure 4.29: MALDI MS Spectra for VPro Feed (A) and VPro Permeate (B) Fractions in 20 mM
Histidine Buffer, pH 5.11
MALDI MS could not resolve the monomers from the higher molecular weight peaks
expected at 171 kDa from CE-SDS. The double-charged ions show at 75 kDa in both instances.
MALDI MS was also used to characterize desalted mAb M, and no monomeric peaks were
observed at 150 kDa.
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4.5 Conclusion
Prefiltration studies of mAb B in section 3 showed that size-exclusion-based prefilters
were not effective in preventing flux decay in virus filters; hence, the focus on adsorptive
prefilters in this section for mAb M. mAb M was generally a well-behaved mAb in histidine
buffers pH 5.11 and pH 6.7 without salt as little fouling occurred. The use of adsorptive prefilters
improved mAb M flux in the VPro and BioEX virus filters, as shown in this section, and
validates earlier results obtained in section 3. However, mAb M was unstable and denatured
rapidly when constituted in pH 5 acetate buffer (20 mM without salt) or when desalted in DI
water.
CE-SDS characterization showed a higher molecular weight monomeric variant of mAb
M decreased from the feed fraction to the BioEX filtrate fraction, as confirmed with mAb B in
section 3. The presence of NaCl in very high concentrations did not significantly denature mAb
M when constituted in histidine buffer thereby showing that histidine is an appropriate buffer for
mAb M storage.
Virus filter fouling is mAb-specific. For mAb M, fouling is chiefly caused by soluble
aggregation of mAb monomers at the virus filtration membrane’s interface. As discussed in this
dissertation, a host of factors can predispose a mAb to soluble aggregation. However, one of the
main reasons adduced for soluble aggregation is the hydrophobicity and charge asymmetry of
mAb variants and denatured monomers which self-associate during the concentration
polarization that occurs at the virus filter’s membrane interface. Hydrophobic patches can
transiently multimerize to slow down the transport of mAbs in the narrow capillaries and cause
flux decay.
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mAb stability plays a considerable role in filterability with virus filters. Factors that
determine the flux behavior of a mAb in virus filter mAb properties, prefilter properties, buffer
excipients, and types of polishing steps used to pretreat the mAb before shipment. We have
shown that arginine and histidine are suitable excipients for mAb M stability. Sodium phosphate
at pH 5 is not a good formulation buffer for mAb M.
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5.0 Ultrafiltration based fractionation of biotherapeutics
5.1 Introduction
The biopharmaceutical industry has seen a rapid transformational growth in the past few
decades, culminating in the complete mapping of the entire human genome [1]. Advances in
gene therapy, cell therapy, and other biologic modalities reinforce the prospect of personalized
medicine. With an exponential increase in the biologics pipeline of biopharmaceutical
companies, robust and cost-effective purification processes have become even more pertinent.
The biopharmaceutical industry is a highly regulated industry where unit operations are mostly
standardized and templated.
There has been increased research in cost-effective biologics purification processes due
to intense competition between biosimilar drug manufacturers and the patent holders of the
biologic reference product [2, 3]. Downstream purification typically represents a significant cost
sink in the biomanufacturing industry [4]. Estimates put a 50-80 percent production cost on
downstream processing compared to the cost of upstream processes [4-7]. Downstream
processing starts at the bioreactor harvest step. It culminates in a purified active
biopharmaceutical ingredient formulated in a stable buffer for fill-finish and delivery to the enduser. Cost optimization efforts have been focused on downstream processing to reduce costs and
maximize profitability.
Fractionation of species similar in size is critical for the validation of virus clearance.
There is less than a two-fold difference in size between mAb monomers and non-enveloped
parvoviruses. When ultrafiltration (UF) or diafiltration (DF) is mentioned, buffer exchange and
product concentration typically come to mind. Ultrafiltration membranes are typically sized
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according to molecular weight cutoffs (MWCO) in kilodaltons (kDa). The steric exclusion
principle ensures that proteins that are significantly larger than the UF membrane's nominal
MWCO are rejected while smaller-sized proteins preferentially pass through. Zydney et al.
(2010) reported that both protein charge and membrane charge play a role in the rate of protein
transport through a UF membrane [8]. Separation of proteins using ultrafiltration membranes
ideally requires a molecular weight ratio (MWR) of 7-10 [9].
The partitioning efficiency of ultrafiltration membranes is around 102, which is below
chromatographic separation partitioning efficiency by two orders of magnitude [9, 10]. The low
resolving power of single stack ultrafiltration membranes has limited the application of UF in
partitioning multi-component protein mixtures with low MWRs. When UF membranes are
stacked in series, the net effect is that a membrane with specific MWCO which is not industrially
available becomes available. Conversely, using multiple single UF membranes in series would
require more buffer flux and offer only commercially available MWCO’s.
By combining the intrinsic charge of a UF membrane with proper buffer pH and ionic
strength, some measure of partitioning between bio-analytes in a two-component protein mixture
can be achieved. Sirkar et al. (2004) demonstrated that a pure protein component could be
obtained from a two-component mixture using multiple UF membranes in a stack (internally
staged ultrafiltration) [11, 12]. It is straightforward to visualize the separation of differently sized
proteins using UF membranes. However, Sirkar et al. showed that similarly sized proteins could
be separated by internally staged ultrafiltration with high purity levels. Electrostatic interactions
are long-range interactions that play a role in the transmission and, by extension, the partitioning
of proteins on an ultrafiltration membrane [8].
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Multiple stacks of UF membranes when applied in internally staged ultrafiltration
amplifies the number of theoretical plates involved in a two-component separation. The intrinsic
charge of these membranes ensures that similarly charged proteins are rejected by the UF
membrane stack while moderately uncharged proteins pass through the UF membrane [13]. Most
commonly available polymeric membranes have a net negative charge in solution due to the
presence of COOH ionizable groups [14]. These negatively charged polymeric membranes
include regenerated cellulose membranes and polyethersulfone (PES) membranes. Figure 5.1
shows an internally staged UF system designed to partition two monoclonal antibodies with
identical molecular masses and isoelectric point differences.

Figure 5.1: Layout of an Internally Staged Ultrafiltration System.
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Figure 5.1 above shows the layout of a three-stage ultrafiltration-based mAb fractionation
system. A mixture of two mAbs can therefore be separated on the basis of differences in
isoelectric point. These two similarly sized mAbs can be separated by leveraging the isoelectric
point difference. The mAb with a higher pI stays negatively charged. The negatively charged
membrane rejects the net negatively charged mAb while the net neutral mAb passes through the
membrane. This principle can also be applied in other biologic modalities, such as charge
partitioning-assisted virus clearance in UF membranes.
5.2 Materials and Methods
5.2.1 Materials
Ultracel regenerated cellulose UF membranes (30 kDa and 100 kDa MWCO flat sheets)
were provided by MilliporeSigma (Billerica, MA). Omega mPES UF membranes (100 kDa and
300 kDa MWCO flat sheets) were provided by Pall Corporation (NY). Sulfhydryl-blocked
bovine serum albumin (BSA) was purchased from Lee Biosolutions (Maryland Heights, MO).
Porcine hemoglobin was purchased as a lyophilized powder from MilliporeSigma (Billerica,
MA).
OmniPur sodium acetate trihydrate (molecular biology grade) and glacial acetic acid
(pharma grade) were sourced from MilliporeSigma (Billerica, MA). MVM (ATCC® VR1346™)
was purchased from American Type Culture Collection (Manassas, VA). Amicon stirred
ultrafiltration cells were provided by MilliporeSigma (Billerica, MA). Ultrapure water with a
resistivity of 18.2 MΩ was used for buffer formulation. Nalgene™ rapid-flow™ sterile singleuse bottle top filters (0.2-μm and 0.1-μm) were purchased from ThermoFisher Scientific
(Waltham, MA).
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5.2.2 Methods
BSA and hemoglobin stock concentration was measured by UV spectrophotometric
analysis at 280 nm using Genesys10 UV Scanning System (Waltham, MA) with VWR quartz
spectrophotometer cell (path length 1 cm; West Chester, PA). Protein concentration was
determined by measuring the absorbance at 280 nm for BSA and 407 nm for hemoglobin.
Minute virus of mice (MVM) was used to perform virus clearance studies. MVM is a parvovirus
referred to as the smallest virus in nature. Virus clearance studies are typically performed with
parvovirus because UF membranes that provide a size cutoff of parvoviruses will ultimately
reject the larger retroviruses.
Production of MVM from stock aliquot was performed by adapting a protocol from
literature (U.S.A. Patent No. EP2377927A1, 2011) [15]. A9 cells (ATCC® CCL-1.4™) were
used to mass-produce the MVM viruses, and the product was purified and centrifuged to desired
values of virus titer. Titers of the MVM product were determined using real-time polymerase
chain reaction (qPCR). The qPCR instrument was a Bio-Rad CFX Connect Real-Time System
(Hercules, CA) with Bio-Rad CFX Manager software. qPCR quantifies the number of copies of
viral genomes in viral samples [15]. The viral titer was calculated by plotting on a standard
curve. Log reduction values of MVM between feed and permeate samples were determined by
subtracting the virus titer of the permeate from that of the feed sample.
BSA, hemoglobin, and MVM solutions were constituted in 2.3 mM sodium acetate
buffer, either at pH 4.8 or pH 6.8. A low conductivity buffer prevents electrostatic shielding of
the negatively charged membrane’s interaction with the proteins. Amicon ultrafiltration stirred
cells are typically used when testing ultrafiltration membranes to prevent concentration
polarization and ensure continuous homogenization of the feed or sample. Flat sheet UF
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membranes are punched to the appropriate diameters and stacked at the bottom of the stirred cell
reservoir before an O-ring is used to ensure a tight seal. Figure 5.2 below shows the workflow
for UF cells in series experiments.

Figure 5.2: Workflow for an Amicon UF Cell in Series Experiment
Figure 5.2 above shows the schematic lines for performing a semi-batch fractionation of
BSA and hemoglobin where the buffer in Amicon cell 1 replenishes Amicon cell 2 during
internally staged ultrafiltration. A single pressurized nitrogen cylinder is used to pressurize both
Amicon cells even though two pressure regulators are required. The pressure is regulated so that
the downstream Amicon cell operates at a lower pressure. This prevents backpressure and
enables buffer flow from Amicon cell 1 into the downstream Amicon cell.
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5.3 Results
5.3.1 Partitioning of Proteins using Internally Staged Ultrafiltration (ISUF)
BSA and hemoglobin were selected as the proteins of interest in a two-component
system. BSA has an isoelectric point of 4.7 and a molecular weight of 66 kDa. Hemoglobin has
an isoelectric point of 6.8 and a molecular weight of 65 kDa. The UF membranes were
previously established to be negatively charged at stated buffer conditions using zeta potential.
These negatively charged membranes were then used in singles, then double stacks. Membranes
were also evaluated by flipping the sides facing the feed stream from the retentive skin side to
the support structure (backing side). Figure 5.3 shows the scanning electron microscopy images
of the 30 kDa ultracel membrane at different magnifications.

Figure 5.3: SEM Images for Skin Side of 30 kDa MWCO RC Ultracel Membrane
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Figure 5.3 above shows that the skin side is the active separation layer. It is homogenous
in pore size distribution, unlike the backing side shown in Figure 5.4 below.

Figure 5.4: SEM Images for the Backing Side of 30 kDa MWCO RC Ultracel Membrane
The support structure (backing) side of the UF membrane provides structural rigidity and
mechanical integrity to the separation-active layer. Ultrafiltration membranes typically have
more open pores and pore size asymmetry on the backing side. The fouling propensity is
typically different with the skin side facing the feed than when the backing side faces the feed.
Flux experiments were performed initially with just BSA to determine the sealing
integrity of the Amicon cell with an Ultracel 30 kDa MWCO membrane, as shown in Figure 5.5
below.
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Figure 5.5: Ultrafiltration using a Single 30 kDa Ultracel RC Membrane to Evaluate BSA
Rejection with (A) Skin Side as Feed-Facing. (B) Backing Side as Feed-Facing.
The BSA and hemoglobin separation experiments typically attain high separation into
single-component systems over long hours of continuous filtration and continuous dilution of
feed in the Amicon cell. If filtration occurs in an Amicon cell without continuous dilution, the
concentration of biomolecules in the Amicon cell goes up. This increases the passage of
undesirable components into the permeate and hinders separation. The absence of a selector
valve connected to a buffer reservoir hinders high purity separation using the ISUF technique.
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5.3.2 MVM Clearance using Internally Staged Ultrafiltration
These experiments were designed to separate MVM from a spiked solution in different
combinations of stacked ultrafiltration membranes. Permeate fractions were collected while
MVM titer was determined with qPCR, as shown in Figure 5.6 below.

Figure 5.6: Ultrafiltration of MVM-spiked, pH 4.8 Acetate Buffer using Double Pall Omega 300
kDa + Pall Omega 100 kDa MWCO Membranes at 3 psi (Backing Sides were Feed-Facing).
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The objective of stacking double ultrafiltration membranes was to evaluate the increment
in virus clearance between one UF membrane and stacked UF membranes. Figure 5.6 is one
example of the virus clearance experiments that were conducted. The rest of the virus clearance
experiments with different membrane stack combinations are shown in Table 5.1.
Table 5.1: Summary of Virus Clearance Experiments for Multiple Configurations of UF
Membranes in Ultrafiltration Stirred Cells.

Table 5.1 shows an increase in the number of membranes per stack and virus clearance. The
backing side of these UF membranes tended to foul in the presence of BSA more than the skin
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side. The backing side often required higher pressure to maintain flow, as shown in row 2 with
the Millipore ultracel 30 kDa backing side (35 psi). The increased pressure potentially resulted in
a loss of amicon cell sealing integrity, leading to increased MVM titer in the permeate and
reduced LRV. All other experiments were conducted at 2 psi for single membranes and 3 psi for
double membranes. A target value of 8 logs feed virus titer was used across experiments
involving single membranes. In comparison, a target of 9 logs feed virus titer was used for the
double membranes. Nine logs represent 109 virus particles, while eight logs represent 108 virus
particles. The increase in feed virus titer for double membranes by 1 log enabled better permeate
virus titer evaluation by qPCR. LRVs were the difference between feed and permeate MVM
titers.
Conclusion
Multi-component systems may be challenging to separate with single UF devices having
a unit molecular weight cutoff. ISUF proffers an alternative option by changing the skin and
backing sides of UF membranes in a stack, thereby attaining unique MWCOs. The pore size of
UF membranes, biomolecular size, and membrane charge are parameters that can be optimized
to obtain effective ISUF systems. Using the ISUF technique, ultrafiltration-based fractionation
can lead to cost-effective purification of industrial pools of biomolecules requiring separation.
Food items such as milk can be made lactose-free in a cost-effective way using UF membranes
to remove lactose in the permeate. Staging the membranes could potentially achieve better
results.
The ISUF technique was used to study MVM (parvovirus) rejection in multi-stack
membranes with multiple configurations, such as Omega PES 300 kDa skin-backing versus
backing skin. The addition of UF membranes to a filtration stack increased the rejection of MVM
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as measured with qPCR, especially when the feed-facing layer was on the skin side of the
membrane. Combining the Omega PES 300 kDa with the Omega PES 100 kDa membrane (skinskin) resulted in 5.5 logs rejection of MVM at pH 4.8. 5.5 logs LRV implies the difference in the
number of virus particles from the feed to the permeate was 105.5 virus particles.
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6.0 Conclusion and Future Directions
A primary goal of this project is to address the high processing costs associated with
mAb production through improvements in mAb prefiltration and virus filtration. This project
was nominated by the industry advisory board and addressed an essential need in the
biopharmaceutical space. This research correlates molecular properties of mAbs in different
buffer conditions to fouling behavior in virus filters and guides prefilter selection criteria.
Some mAb variants with post-translational modifications have micro heterogeneous
attributes that could increase fouling propensity, including loss of native-state conformations,
charge variation, and hydrophobicity variation. mAb monomeric variants could foul virus filters
through adsorptive cake formation or by forming reversible multimers that plug the virus filter
pores.
Principally fouling mAb variants can be captured by optimizing the prefiltration process
before virus filtration. The capture of principally fouling mAb variants enables longer runtimes
for virus filter banks with seamless operations and fewer process downtimes, thereby reducing
cost. Hydrophobic interaction chromatography membrane adsorbers were found to be very
robust for mAb prefiltration in the buffer conditions evaluated for mAb B and M, including
acetate buffers of pH 5, 7.5, and 8.6, as well as histidine only buffer of pH 5.1 and pH 6.7.
Future work could evaluate multiple mAb products from more biopharmaceutical
companies to increase the data set for a machine learning model. Emphasis can be placed on
mAb variant partitioning and characterization to identify mAb variants with high fouling index
and create a guideline for prefilter selection. More work should be performed using virus filters
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and prefilters from multiple manufacturers. Efforts should be made toward the assessment of
multimodal prefilters and their impact on mitigating virus filter flux decay.
Further studies should try to identify mAb PTMs which promote rapid flux decay during
virus filtration while critically examining the impact of mAb glycosylation on mAb filterability
and stability. A filterability index for mAb products using experimental data would be the
outcome of this expected database. A machine learning model could match mAb sequence,
native conformation, PTMs, hydrophobicity, and solution conditions to filterability in different
prefilter and virus filter types. The machine learning model would be a template for
biopharmaceutical companies in process development for mAb production trains.
Optimizing the mAb formulation buffer during prefiltration will provide
biopharmaceutical companies with a robust template for process development, maximize the
performance of the virus filter and reduce drug end-user costs. Insights into the nature and
characteristics of principal foulants can also help virus filter manufacturers to improve the design
of virus filters for increased utility and safety. The intravenous mode of administering
monoclonal antibodies to patients justifies investment in this research to improve mAb product
safety and reduce the cost of mAb manufacture.
Based on the general scientific view that soluble aggregation causes virus filter fouling,
as seen in multiple peer-reviewed publications and not disproved by our work, virus filter
manufacturers can perform more flow field studies to design virus filtration membranes with
better pore geometry that could mitigate plugging.
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Appendix A: Supplementary Chromatograms for Adsorptive Prefiltration of mAb B

i

ii
Figure A1: Chromatograms for HIC Prefiltration of mAb B in 20 mM Sodium Acetate Buffer at
(i) pH 7.5 with 200 mM NaCl. (ii) pH 8.6 with 200 mM NaCl.

160

i

ii

Figure A2: Chromatograms for IEX-S Prefiltration of mAb B in 20 mM Sodium Acetate Buffer
at (i) pH 7.5 without Salt. (ii) pH 8.6 with 200 mM NaCl.
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i

ii

Figure A3: Chromatograms for IEX-Q Prefiltration of mAb B in 20 mM Sodium Acetate Buffer
at (i) pH 5 with 200 mM NaCl. (ii) pH 8.6 with 200 mM NaCl.
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Appendix B: Supplementary Characterization for mAb B Bind-and-Elute Fractionation

i

ii
Figure B1: Capillary Zone Electrophoresis of mAb B Fractionated by Gradient Elution using a
Capto S Cation Exchange Column after Bind-and-Elute (Buffer A: 20 mM Sodium Acetate, pH
6.5, No Salt. Buffer B: pH 8.6, 20 mM Sodium Acetate with 200 mM NaCl). (i) Composite Plot
for Fractions 2 - 6. (ii) Plot of Capto S Eluate Fractions 2 and 3 Only.
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Appendix C: mAb B partitioning using cation exchange columns in bind-and-elute mode
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Figure C1: IEX-S Bind-and-Elute Chromatograms for Charge Variant Partitioning of mAb B in
20 mM Sodium Acetate Buffer (i) pH 5 without Salt. (ii) pH 6.5 without Salt.
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Figure C2: Capto-S Bind-and-Elute Chromatograms for Charge Variant Partitioning of 0.5 g/L
mAb B in 20 mM Sodium Acetate Buffer at pH 6.5 without Salt.
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Appendix D: Glycan Profiles of mAb B Determined using Capillary Electrophoresis
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Figure D1: Fast Glycan Analysis Characterization of mAb B BioEX Filtration fractions in DI
Water after PNGase Deglycosylation and Glycan Purification by Solid-Phase Extraction.
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(i) Fast Glycan Electropherogram for mAb B Feed Desalted and Reconstituted in DI Water
before Deglycosylation. (ii) Peak Integration Derived Quantification of Relative Percentages of
Glycan Types in mAb B Feed, BioEX Filtrate, and HIC Eluate. MW of Each Glycan Category is
included for Clarity.
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Appendix E: SEC data for mAb B prefiltration and virus filtration fractions
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Figure E1: 220 nm Absorbance Spectra for TSKgel HPLC SEC Characterization of (i) mAb B
Feed in 20 mM Sodium Acetate Buffer (pH 5 with 200 mM NaCl), BioEX Buffer Chase (pH 5
with 200 mM NaCl), BioEX Eluate Fractions (pH 4 and pH 9 without Salt), HIC Wash (pH 5
with 200 mM NaCl), and IEX-S Eluate Fraction (pH 5 with 1 M NaCl). (ii) HIC pH 4 Backwash.
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Figure E2: Dimer Quantitation from TSKgel HPLC SEC Characterization of mAb B BioEX
Feed, Permeate and Buffer Chase in 20 mM Sodium Acetate Buffer without Salt, pH 7.5.
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Appendix F: DLS data for mAb B prefiltration and virus filtration fractions

Figure F1: DLS Spectra of mAb B HIC, IEX-S, and BioEX Filtration Fractions
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